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Aims: This thesis had three aims: to review evidence evaluating the effectiveness of 
decision aids at increasing cancer patients’ treatment-related knowledge and reducing 
decisional conflict; to explore the decision-making processes of ovarian cancer 
patients who had opted for or against CA-125 testing during post-treatment 
surveillance; and to elicit patients’ and health professionals’ views on the proposed 
development of a decision aid aimed at helping women decide for or against CA-125 
testing during post-treatment surveillance for ovarian cancer.  
 
Methods: A systematic review was conducted of evidence relating to the 
effectiveness of cancer treatment-related decision aids at increasing treatment-related 
knowledge and reducing decisional conflict. In the qualitative study, semi-structured 
interviews were conducted with ovarian cancer patients (n = 18) and health 
professionals (n = 6) in an outpatient gynecological oncology clinic. Framework 
analysis was used to identify themes in the qualitative data. 
 
Results: Overall, results from the systematic review supported previous research 
where decision aids were found to improve patient knowledge and reduce decisional 
conflict across a range of cancer treatment-related decisions. However, the lack of 
psychometric support for the treatment-related knowledge measures used in the 
majority of the studies compromised their ability to address the review question. In 
the qualitative study, accurate knowledge about CA-125 testing in post-treatment 
surveillance was found to greatly influence participants’ decision-making processes. 
Most women with less knowledge about the test chose to have testing based on the 
false belief that earlier detection of recurrence would lead to earlier treatment and 
prolonged survival. There was strong enthusiasm from patients and health 
professionals for the development of the proposed decision aid to assist women facing 
this treatment decision.  
 
Conclusions: The systematic review findings add to previous research supporting the 
use of decision aids in cancer-related treatment decisions and advocate for their 
! 2 
continued development, evaluation and implementation into the healthcare system. 
The need for a decision aid to ensure accurate knowledge about CA-125 and to aid 
decision-making for women with ovarian cancer was supported. As well as assisting 
women with this decision, the proposed decision aid may ultimately support health 
professionals in practicing shared decision-making regarding CA-125 testing with 
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Background: A small number of systematic reviews have found support for the 
effectiveness of patient decision aids in increasing knowledge and reducing decisional 
conflict in cancer treatment-related decisions. However, reviews have tended to only 
include randomized controlled trials and explored a limited number of cancer 
diagnoses. This review aimed to evaluate the effectiveness of treatment-related 
decision aids at increasing patient knowledge and reducing decisional conflict, 
regardless of cancer type or study design.  
 
Methods: Multiple electronic databases were systematically searched and reference 
lists of identified articles were scanned. Twelve studies were methodologically 
appraised using quality criteria developed to address the review question. 
 
Results: Results supported previous research where decision aids were found to 
improve patient knowledge and reduce decisional conflict across a range of cancer 
treatment-related decisions. In the controlled studies, patients receiving decision aids 
had higher knowledge and lower decisional conflict scores compared with controls. 
However, the lack of psychometric support for the treatment-related knowledge 
measures used in six out of the seven studies compromised their ability to address the 
review question.  
 
Conclusion: The findings add to previous research supporting the use of decision aids 
in cancer-related treatment decisions and advocate for their continued development, 
evaluation and implementation into the healthcare system.  
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Keywords: Cancer, treatment, knowledge, decisional conflict, decision aids, decision-
making 
 





In recent decades, greater emphasis has been placed on the importance of shared 
decision-making (SDM) in healthcare systems worldwide (Joseph-William et al 
2014). In the United Kingdom, SDM is embedded within the National Health Service 
where the motto of “No decision about me without me” encapsulates the vision of the 
service to develop a more patient-centred healthcare system (Department of Health, 
2012). SDM is “the process of interacting with patients who wish to be involved in 
arriving at an informed, values-based choice among two or more medically 
reasonable alternatives” (O’Connor et al, 2004, pp. 64). In cancer care, existing health 
literature suggests that most patients prefer an active role in treatment-related 
decision-making (Stewart et al 2000; Gattellari et al, 2001; Keating et al, 2002; 
Stacey et al, 2010). However, barriers exist for patients to engage properly in the 
decision-making process. Apart from the emotional burden of adjusting to the cancer 
diagnosis itself, patients are often faced with ‘preference-sensitive’ decisions, where 
two or more medically equivalent treatment options exist with varying degrees of 
potential benefits and side effects. In these situations, patients must make an informed 
decision that is consistent with their values (Stacey et al, 2008).  
 
There has been a significant investment in the development of decision support tools, 
particularly decision aids (DAs), to assist patients and health professionals with 
preference-sensitive decision-making and to encourage SDM. DAs are evidence-
based tools that assist patients with preference-sensitive decision making by outlining 
the decision that needs to be made, informing patients about the options and outcomes 
and by clarifying patients’ personal values for the benefits versus harms of the 
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different options available (O’Connor et al, 2007). DAs come in a variety of formats 
including booklets, decision boards, computer programmes, videos and interactive 
websites, but differ from usual health education materials because of their 
individualised focus on options and outcomes (O’Connor et al, 2009).  
 
DA development is closely linked with The Conflict Theory of Decision Making 
(Janis & Mann, 1977), which is based on the key assumption that a life-altering 
situation that produces a decision dilemma leads a person to experience decisional 
conflict, which generates a certain degree of stress.!According to the theory, this stress 
arises from concern about personal and material losses that may occur from the 
chosen alternative, as well as from concern about the subjective losses that may lower 
self esteem (Janis & Mann, 1979). The theory assumes that in coping with this stress, 
an individual chooses one of five coping patterns during the process of trying to 
resolve the decisional conflict: (1) unconflicted adherence; (2) unconflicted change; 
(3) defensive avoidance; (4) hypervigilance; and (5) vigilance. According to the 
model, the first four coping patterns (where there is an absence or excess of stress) are 
maladaptive and associated with unproductive information search, assessment and 
decision making patterns. Only the last of these, vigilance, is adaptive, where an 
individual will seek out information and weigh the options carefully. Deliberation 
tools such as decision aids are designed to help individuals accomplish these goals as 
information is organized in such a way as to provide clarity about the nature of the 




Systematic reviews of clinical trials assessing the effectiveness of DAs for cancer-
related decisions have reported improvements across a number of decision-related 
outcomes (Waljee et al, 2007; Stacey et al, 2008; O’Brien et al, 2009; Spiegle et al, 
2013). As highlighted by Neuman and colleagues (2007), whilst it may seem 
intuitively obvious that DAs would help patients to make health-related decisions, it is 
important to objectively evaluate this. Health professionals must also be confident of 
the efficacy of DAs in order to invest their time in using them and facilitating their 
implementation within everyday clinical practice. Additionally, health service 
managers and policymakers also need strong evidence of DA efficacy in order to 
provide support and funding for their development, evaluation and implementation.  
 
Knowledge and decisional conflict (DC) are important outcome variables by which to 
judge the effectiveness of DAs. Health care professionals are bound by both legal and 
ethical obligations to ensure that patients provide informed consent for treatment-
related decisions (Feldman-Stewart et al, 2013). Knowledge is a prerequisite for 
informed decision-making, ensuring that patients make choices in line with their 
personal values (Smith et al, 2012). A wide variety of both prescriptive and 
descriptive theories of decision-making all suggest that a solid knowledge base of the 
decision-related problem needs to be developed by patients in order to establish 
personal, knowledge-based preferences (Feldman-Stewart et al, 2013). The primary 
goal of DAs is to increase patients’ knowledge about their condition and present 
unbiased and balanced information about their treatment options (O’Connor et al, 
2003). A recent Cochrane review comparing DAs to usual care in terms of the effects 
of knowledge scores found that patients using DAs had significantly higher scores 
(Stacey et al, 2014).  
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According to the Ottawa Decision Support Framework, DC is a key determinant in 
decision-making (ODSF 2014). DC is commonly experienced by patients where 
preference-sensitive decisions are involved, where there is a ‘choice dilemma’ or 
‘conflicted decision’ that leads to a feeling of uncertainty (O’Connor & Jacobsen, 
2007). According to DC theory, several modifiable deficits can increase or decrease 
the level of uncertainty perceived by patients facing health-related decisions 
including: (1) feeling uniformed; 2) unclear values regarding the relative desirability 
or importance of the benefit versus harm of the available options; 3) perceived 
inadequate support; and 4) the overall perception that a poor quality or ineffective 
decision has been made (O’Connor & Jacobsen, 2007). A recent study found that 
cancer patients who had greater involvement in decision-making had significantly less 
DC as compared to patients with less involvement (Brown et al, 2012). Similar to 
knowledge, evaluation research has supported the use of DAs for reducing DC in 
cancer-related treatment decisions (Stacey et al, 2014).  
 
Rationale for the current review 
 
To date, systematic reviews specifically assessing the effectiveness of cancer 
treatment-related DAs have been limited by a focus on published studies using a RCT 
design only (O’Brien et al, 2009; Spiegle et al, 2013), thus excluding the opportunity 
for a wider review of non-randomised or non-controlled studies that may provide 
additional insight into DA effectiveness. The results of one of these studies largely 
reflected DAs in the cancer screening context, with only 5 out of the 34 studies 
included in the review relating to treatment, thus limiting the ability for the results to 
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be definitive about the impact of cancer-related DAs in the treatment context 
(O’Brien et al, 2009). Additionally, the focus in the second related study was limited 
to only four specific cancer diagnoses from the outset: breast; colorectal; lung; and 
prostate (Spiegle et al, 2013). This highlights the paucity of research evidence 
assessing the effectiveness of DAs in other cancer diagnoses in the treatment context.   
 
Main Aim of the Systematic Review 
 
The current review aims to systematically evaluate the effectiveness of cancer 
treatment-related DAs at increasing patient treatment-related knowledge and reducing 







As a first step, the Cochrane Database of Abstracts of Reviews and Effects (DARE) 
was searched in order to ensure that a similar review had not been recently conducted. 
The DARE search identified four articles that were related to the current review: first, 
a systematic review on the feasibility and effects of DAs (Molenaar et al, 2000); 
second, a systematic review on the impact of cancer-related DAs (O’Brien et al, 
2002); third, a systematic review and meta-analysis of the effectiveness of cancer-
related DAs in screening, prevention and treatment (O’Brien et al, 2009); and fourth, 
a systematic review on DAs for health treatment or screening decisions (Stacey et al, 
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2014). Subsequently, as recommended in guidance for undertaking reviews in 
healthcare produced by York University’s Centre for Reviews and Dissemination 
(CRD, 2009), a study selection protocol was developed prior to undertaking the 
literature search in order to minimize bias and facilitate transparency. The protocol 
comprised an outline of the review question, the rationale for the review, a definition 
of a DA, eligibility criteria, outcomes of interest, planned search strategy, planned 
data extraction methods, quality assessment methods and the intended method of 




Inclusion & exclusion criteria 
 
Studies were retained for review if they: (a) quantitatively evaluated a decision aid for 
adult patients with a histologically-proven cancer diagnosis facing a choice related to 
treatment; and (b) included outcome measures of treatment-related knowledge and/or 
decisional conflict pre and post the decision aid intervention; and (c) had a minimum 
sample size of 10 participants. Studies were excluded where full text articles could 
not be sourced either as a complete published article or by contacting the authors 
directly for complete unpublished drafts.  
 
Literature search strategies 
 
The literature search was conducted in February 2014. Systematic searches of 
relevant databases were undertaken and all databases selected were searched from 
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their inception. MEDLINE (1946 to February 2014), PsychInfo (1974 to February 
2014), CINAHL Plus (Cumulative Index of Nursing and Allied Health Literature; 
1982 to February 2014), EMBASE (1947 to February 2014), Sociological Abstracts 
(1952 to February 2014) and the Cochrane Library (1994 to February 2014) were all 
searched for relevant titles. The following search string was used within each 
database: (‘decision aid’ OR ‘decision support technique*’ OR ‘decision tool’ OR 
‘decision support system*’ OR ‘education* aid’ OR ‘education* tool’) AND (‘cancer’ 
OR ‘neoplasm*’) AND ‘treatment’. Additionally, relevant journals within the years 
2009 to 2014 were hand searched: Medical Decision Making, Patient Education & 





Figure 1 provides an overview of the search selection process and details each stage. 
Of 2846 potentially eligible articles, 223 abstracts were screened for eligibility and 40 
full-text articles were retrieved. The search process was completed by a manual hand 
search of the reference lists of these 40 studies in order to detect any studies that may 
have been missed. A further four reviews were identified during this process. In 
addition, the reference lists of the four reviews identified during the DARE search 
(Molenaar et al, 2000; O’Brien et al, 2002; O’Brien et al, 2009; Stacey et al, 2014) 
were screened but no further studies were identified. Thirty-two of the 44 studies 
were excluded for reasons provided in Table 1. The remaining 12 studies were 





Table 1. Overview of excluded studies following full text review 
No. of Studies 
Excluded 
Reason for Exclusion (n = 32) 
11 Did not assess treatment-related knowledge and / or DC  
8 Did not assess treatment-related knowledge and/or DC pre and post the 
DA intervention 
4 DA pilot studies 
4 Qualitative DA evaluation studies 
3 Participants without a histologically-proven cancer diagnosis 
1 Less than 10 participants 
















2,846 records identified 
through database searching 
2,792 records after 54 
duplicates removed 
223 abstracts screened 
40 full texts assessed for 
eligibility 
4 additional records identified 
through reference list & hand 
searching 
12 studies retained 
179 records excluded. Reasons 
for exclusions: 
• DA Descriptive Studies!
• DA Development 
Studies!
• DA Evaluation Studies!
• DA Feasibility Studies!
• Decision Analysis 
Studies!
  
32 full text articles excluded 





Information was collated using a data extraction form for each of the 12 studies 
included in the final selection for systematic review. This included study 
characteristics, participant characteristics, intervention, setting and main study 
findings (Table 3).  
 
Assessment of methodological quality 
 
As there was no existing quality criteria checklist appropriate for this review, quality 
criteria pertinent to the current review question were developed by the authors 
(Appendix 3). As recommended by the CRD, the quality criteria encompassed the 
assessment of: the risk of bias; the choice of outcome measure; statistical issues; and 
external validity (www.york.ac.uk/inst/crd/). F.E.W rated each of the 12 studies in 
relation to 10 quality criteria developed using the following six outcome ratings: ‘well 
covered’; ‘adequately addressed’; ‘poorly addressed’; ‘not addressed’; ‘not reported’; 
or ‘not applicable’. The following overall quality ratings, originally created by author 
P.G.M and adapted to fit the current review, were assigned to the studies: excellent; 
good; adequate; or poor (Table 2). Eight out of the twelve papers (66.6%) were 
independently rated by two researchers, where P.G.M independently reviewed three 
papers and a further five papers were rated by a trainee clinical psychologist (C.G). 
Rating discrepancies were discussed and all authors reached a joint decision on the 






Table 2. Overall methodological quality ratings 
!
Excellent 
All or a considerable majority of the criteria have been well covered. 
Limitations of the study are thought to be very unlikely to have affected the 
findings or conclusions. 
Good 
Considerable majority of the criteria have been well covered or adequately 
addressed. Limitations of the study are thought to be unlikely to have 
affected the findings or conclusions. 
Adequate 
Majority of the criteria have been well covered or adequately addressed. 
Limitations of the study may have modestly affected the findings or 
conclusions. 
Poor 
Many or most criteria were not well covered or adequately addressed. 
Limitations of the study are thought likely or very likely to have affected 




Table 1. Overview of selected studies 
Author & Year Cancer Type 
Treatment Options outlined 












Measures Main Findings 
Berry et al 2013 
USA Prostate 
Watchful waiting OR external 
beam radiation therapy and 
brachytherapy OR surgery 
(prostatectomy) 
RCT  266 Y-228 DCS 
Compared with controls, significantly reduced DC for 
the two subscales of uncertainty and values clarity. 
Borderline effect for the Total DC scale but reduction 
not significant in the remaining three subscales 
Collins et al 2009 
USA Breast 
Mastectomy OR breast 
conserving surgery with 
radiotherapy 
Pre/post study 125 N  DCS  
Significant reduction in DC over time with biggest 
reductions on the informed and values clarity 
subscales 
Davidson et al 2007 
Canada Prostate 
Surgery (prostatectomy) OR 
external beam radiation 
therapy and brachytherapy 




Levels of DC lower for both groups post DA but no 
significant differences between groups found 




Surgery (prostatectomy) OR 
external beam radiation 
therapy and brachytherapy 
RCT  81 Y-75 DCS No difference between groups either at baseline or post-DA, decrease in DC for both groups 
Fiset et al 2000 
Canada Lung 
Supportive care with 
palliative radiation therapy 
OR supportive care with 
palliative radiation therapy 
and chemotherapy 
Pre/post study 20 N  
Knowledge 
questionnair
e & DCS 
Knowledge scores improved significantly post-DA 




Mastectomy OR breast 
conserving therapy with 
radiotherapy 





re & DCS 
Significant improvement in overall knowledge scores 
for DA group post-DA versus control group. 
Decreased DC scores for both groups over time but 
significantly lower scores for DA group participants 
in the informed and values clarity subscales 
 
Peate et al 2012 
Australia Breast 
Wait and see OR in vitro 
fertilisation (IVF) OR egg 









DA group had greater reduction in DC than those who 
received usual care over 12 months 
Use of the DA significantly improved fertility-related 
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Author & Year Cancer Type 
Treatment Options outlined 












Measures Main Findings 
freezing OR ovarian 
suppression OR egg and 
embryo donation 
knowledge with significant difference reported in DA 
versus control group 
Sivell et al 2012 
UK Breast 
Mastectomy OR breast 
conserving surgery with 
radiotherapy 
Pre/post study 54 N  10 true/false questions 
Mean knowledge scores high both pre and post-DA. 
Increase in scores post-DA but not significant 
Street et al 1995 
USA Breast 
Mastectomy OR breast 
conserving surgery with 
radiotherapy 




Knowledge scores significantly improved for both 
groups post-DA. No significant difference between 
groups according to DA format 
Van Tol-Geerdink et al 
2008 
Netherlands 




Significant improvement in subjective & objective 
knowledge in the DA group versus control group 
Vodermaier et al 2009 
Germany Breast 
(1) Mastectomy OR 
lumpectomy and radiation 
(tumour size T1 group) 
 (2) Preoperative 
chemotherapy followed by 
surgery OR standard therapy 
(surgery followed by 
chemotherapy choices 
(tumour size T2/ T3 group) 
RCT 55 Y-56 DCS 
No intervention effect emerged on the Total DC scale. 
A significant group effect emerged on the informed 
subscale 
Whelan et al 1995 
Canada Breast 
Breast irradiation post-
lumpectomy OR no treatment 
post-lumpectomy 
Pre/post study 30 Y-52 10 true/false statements 
Patient knowledge was similar between groups but 
patients who used the decision board had increased 
understanding regarding the fact that breast irradiation 
could not be repeated 
 






Characteristics of included studies 
 
As summarized in Table 3, 12 quantitative studies undertaken in six countries 
between 1995 and 2013 were selected for appraisal and review of their 
methodological quality. Of the 12 studies included, four were RCTs and eight were 
non-RCTs (using a pre/post intervention study design). Four of the eight non-RCT 
studies were prospective cohort studies and the remaining four studies compared one 
form of DA to another. Decision aids used in breast, lung and prostate cancers were 
studied. Four of the reviewed studies focused on knowledge, five focused on 
decisional conflict, and three considered both knowledge and decisional conflict. A 
total of 2056 patients were included with sample sizes ranging from 20 to 494 
participants. Decision aids were offered by means of interactive computer 
programmes, booklets, videos with/without linear booklets and decision boards. 
Details of participants’ treatment options are presented in Table 3.  
 
Quality of included studies 
 
Table 4 provides ratings for each of the studies on the 10 quality criteria.!In!relation!
to! addressing! the! review! question,! included! studies! were! of! good!methodological!
quality! overall,! with! 8! of! the! 12! papers! achieving! a!well<covered! score! on! five! or!
more!quality! criteria.!Berry et al (2013) stood out as the most rigorous in terms of 
design and methodology, achieving the highest rating (well-covered) in all nine 
applicable categories. In terms of reviewing the quality of the included studies, the 
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aspects of study design that are particularly pertinent to answering this review 
question relate to the representativeness of the clinical sample and the outcome 
measures selected for treatment-related knowledge and decisional conflict. 
 
Regarding representativeness, a true clinical sample of patients was represented in the 
majority of studies (well-covered/adequately addressed), where a consecutive series 
of potential patients had been approached in a clinical setting(s), of which over 60% 
completed the study. In terms of number of recruitment sites, two studies in particular 
stood out as being especially strong in this category. Peate et al (2012) recruited 
across 19 sites and Berry et al (2013) recruited across 6 sites, thus contributing to the 
external validity, reliability and generalisability of their results. This was in contrast 
to the majority of included studies whose recruitment was limited to one clinical 
location (Street et al, 1995; Whelan et al, 1995; Fiset et al, 2000; Davidson et al, 
2007; Collins et al, 2009; Vodermaier et al, 2009; Feldman-Stewart et al, 2012). 
 
Regarding the measurement of patient treatment-related knowledge, six out of seven 
studies were allocated a poorly addressed rating as they used non-standardised 
instruments developed by the authors, generally consisting of true or false statements. 
The Jibaba-Weiss et al (2012) study stands out compared to the other six studies 
evaluating the effectiveness of the DA on this outcome, as it was the only study to 
report internal consistency for their developed scale (Cronbach’s alpha = 0.63). 
However, the knowledge measure used was not included within the journal article. 
Indeed, the knowledge scales developed were only included in three of the seven 
articles (Street et al, 1995; Whelan et al, 1995; Sivell et al, 2012). Thus, measures 
used to assess knowledge in six of the seven studies were not established to be valid 
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and reliable for the relevant populations, which significantly limits the ability of these 
studies to address the review question.  
 
In contrast, all eight studies assessing DC used a version of the validated and reliable 
Decisional Conflict Scale (DCS; O’Connor, 1995). The full DCS version comprises 
16 items, within five sub-scales. The first four sub-scales elicit the extent to which a 
person feels: certain, informed, clear regarding their values, and supported in 
decision-making. The last sub-scale elicits the person’s overall perception of the 
effectiveness of the decision-making process. Each item is scored on a 5-point Likert 
scale (1, strongly agree to; 5, strongly disagree). The DCS total score is obtained by 
summing up the 16 item scores and dividing by 16, resulting in a score that ranges 
from 1 to 5. A higher score indicates a higher level of DC (i.e. more discomfort with 
the decision made). This is a widely used scale that is sensitive to change and shows 
excellent validity and reliability. Five of the eight studies used the complete 16-item 
instrument (O’Connor, 1995), with one using the German-translated version 
(Vodermaier et al, 2009). The remaining three studies used the low-literacy version of 
the DCS, a 10-item shorter version (made up of four subscales), which is 
recommended for those with limited reading or response skills (O’Connor, 2010). The 
use of a psychometrically sound measure across these studies increases confidence in 
the findings related to patients’ DC post-DA exposure. 
 
Regarding the remaining quality criteria, most studies with control groups had applied 
randomization, which reduced the risk of bias. Follow-up of outcome measures post-
DA intervention was reported in half of the studies, where four of the six studies 
carried out follow-up for a minimum of three months. As evident in Table 4, analyses 
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in the majority of studies were appropriately reported and justified, with some 





Table 1. Overview of methodological quality ratings 
Study 















































































































Berry et al (2013) W/C W/C W/C W/C W/C N/APP W/C W/C W/C W/C Excellent 
Collins et al (2009) P/A N/ADD N/ADD W/C N/ADD N/APP W/C W/C A/A P/A Poor 
Davison et al (2007) P/A W/C W/C W/C W/C N/APP W/C A/A N/R N/ADD Good 
Fiset et al (2000) A/A N/ADD N/ADD P/A N/ADD P/A W/C W/C N/R N/ADD Poor 
Feldman-Stewart et al (2012) P/A A/A W/C W/C W/C N/APP W/C W/C W/C N/ADD Good 
Jibaba-Weiss et al (2011) A/A W/C W/C A/A N/R A/A W/C W/C W/C W/C Good 
Peate et al (2012) W/C W/C N/ADD A/A A/A P/A W/C W/C W/C W/C Good 
Sivell et al (2012) P/A N/ADD N/ADD A/A N/ADD P/A N/APP W/C A/A N/ADD Poor 
Street et al (1995) W/C A/A W/C P/A W/C P/A N/APP W/C W/C N/ADD Adequate 
Van Tol-Geerdink et al (2008) A/A W/C N/ADD W/C W/C P/A N/APP W/C W/C W/C Good 
Vodermaier et al (2009) A/A W/C W/C W/C N/R N/APP W/C A/A W/C P/A Adequate 
Whelan et al (1995) W/C W/C P/A P/A N/R P/A N/APP A/A P/A N/ADD Poor 
              W/C Well Covered 
!
A/A Adequately Addressed 
!
P/A Poorly Addressed 
N/ADD Not Addressed 
!
N/R Not Reported 
!
N/APP Not Applicable 
              1 A true clinical sample of patients was represented in the study 6 Knowledge outcome was measured in a valid and reliable way 
2 A suitably controlled design was used 7 Decisional conflict outcome was measured in a valid and reliable way 
3 Assignment to groups was randomised 8 Appropriate analyses used 
4 Sample size was sufficient for analyses relating to knowledge and/or decisional conflict outcomes 9 Levels of attrition were equivalent for treatment versus control 





Narrative Synthesis  
 
Two outcomes, treatment-related knowledge and DC, were considered for 
quantitative meta-analysis. As aforementioned, in the studies assessing patient 
treatment-related knowledge, several different methods were used, and the majority of 
these studies did not provide evidence of the validity or reliability of their knowledge 
scale. The heterogeneity of methods and measures and lack of standardized 
questionnaire use made a meta-analysis impractical for the knowledge outcome. 
Similarly, in the studies assessing DC, meta-analysis was not possible due to the 
heterogeneity of the studies in terms of their methodology and DCS versions used. As 
a result, a narrative description of the results is provided. 
 
Patient Treatment-Related Knowledge 
 
Among the seven studies measuring treatment-related knowledge, the DAs appeared 
to increase patients’ knowledge concerning the cancer and its related treatment 
options, with all seven studies reporting an increase in patient knowledge scores 
following DA-exposure (Street et al, 1995; Whelan et al, 1995; Fiset et al, 2000; van 
Tol-Geerdink et al, 2008; Jibaba-Weiss et al, 2011; Peate et al, 2012; Sivell et al, 
2012). This difference was statistically significant for participants in five of the seven 
studies (Fiset et al, 2000; Jibaba-Weiss et al, 2011; Peate et al, 2012; Street et al, 
1995; Whelan et al, 1995). However, it is important to note that the lack of 
psychometric support for the measures used in six out of the seven studies assessing 
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treatment-related knowledge compromises their ability to confidently address the 
review question.  
 
It is important to consider methodological issues within the included studies in 
relation to the results. In the first of the two cohort studies, Fiset et al (2000) found a 
significant improvement in knowledge scores (p < 0.001) from a mean of 72% correct 
answers at baseline to 90% after DA-exposure. However, this study only achieved an 
adequate quality rating overall, with a small sample size (n = 20), which highlights 
the need for caution when interpreting the results. The second cohort study was also 
methodologically weak in comparison to the majority of included studies. Sivell et al 
(2012) found that although knowledge scores on their 10-item questionnaire increased 
after DA exposure, the increase was not significant (baseline mean = 8.28, post-
intervention mean = 8.51). The authors acknowledged that this lack of improvement 
might reflect the lack of validity and reliability of the measure. It is also worth noting 
that only women who requested further information on surgery following the standard 
pre-surgical consultation were invited to use the DA. Thus, it is unsurprising that their 
pre-DA scores were also high relating to treatment-related knowledge. The results 
were in contrast to those of the other two studies assessing treatment-related 
knowledge surrounding the decision to opt for mastectomy or breast conserving 
surgery and radiation for breast cancer (Street et al, 1995; Jibaba-Weiss et al, 2011), 
where a significant difference in knowledge scores post-DA was reported in both. 
 
Four studies compared DA with usual care (Whelan et al, 1995; van Tol-Geerdink et 
al, 2008; Jibaba-Weiss et al, 2011; Peate et al, 2012). Inclusion of a control group is 
likely to have helped eliminate possible alternative explanations of the results related 
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to treatment-related knowledge following DA exposure. In three of these four studies, 
the DA group had significantly higher than average knowledge scores (van Tol-
Geerdink et al, 2008; Jibaba-Weiss et al, 2011; Peate et al, 2012). For example, van 
Tol-Geerdink et al (2008) found that subjective knowledge (means 6.8 versus 6.3, p < 
0.001) and objective knowledge (means 6.9 versus 4.4, p < 0.001) improved in the 
DA over the control group. The fourth study reported similarities between the DA and 
control groups on all but one knowledge question, where patients who used the DA 
had increased understanding of the fact that breast irradiation could not be repeated to 
the same breast (p < 0.001) (Whelan et al, 1995). However, this study was notably 
weaker in methodological quality compared to the three other studies, particularly 
regarding sample size and attrition levels. Out of the two studies with follow-up 
assessments (Jibaba-Weiss et al, 2011; Peate et al, 2012), one maintained long-term 
follow-up scores (Peate et al, 2012). However, the control group in the second study’s 
knowledge had increased almost to the level of the DA intervention group at 1-year 
follow-up (Jibaba-Weiss et al, 2011). Of note, however, the time from T2 to T3 in the 
latter study varied from a few days to almost one year. Therefore, patients may have 
become more knowledgeable about treatment over time, which could have affected 
outcomes.  
 
The final study randomly allocated participants to a brochure format DA versus a 
computer programme DA (Street et al, 1995). Knowledge scores on an 11-item 
multiple-choice questionnaire were assessed at baseline, post-DA and post-
consultation. Repeated measures ANOVAs assessed knowledge means by 
experimental condition and time.  A strong effect for time was found at Time 1 versus 
Time 2 (F = 36.35, p < 0.001) but knowledge scores after the consultation were 
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essentially the same as post-DA exposure scores. The effect for method of education 
(brochure versus computerized programme) approached significance (F = 3.30, p = 
0.07), as patients in the computer group tended to learn more than the brochure group. 
However, limitations of the study included the lack of a ‘no education’ group and a 




All eight studies assessing DC reported a significant decrease in DC in treatment 
decision-making on subscales of the DCS post-DA exposure. The two prospective 
cohort studies reported statistically significant reductions in DC over time (Fiset et al, 
2000; Collins et al, 2009). Collins and colleagues (2009) assessed DC over three time 
points (baseline, post-DA and post-surgical consultation) and reported that reductions 
in overall DC were primarily driven by two subscales: feeling informed and unclear 
about personal values (paired t test P < .01). However, this study was conducted at a 
single medical centre where decisional support is incorporated into the clinical care 
process. It is therefore likely that patients in this system would have lower than usual 
baseline DC scores compared to patients who do not receive decisional support as 
routine practice. Fiset and colleagues (2000) also reported a statistically significant 
decline in DC (P < 0.001), with the mean score declining by 0.6 out of 5 (95% CI: 
0.4, 0.8), where the smallest change was noted in the support subscale. However, 





 Three of the four RCTs assessing differences between DA versus control groups 
reported statistically significant reductions in DC (Jibaba-Weiss et al, 2011; Peate et 
al, 2012; Berry et al 2013). For example, Peate and colleagues (2012) found that 
compared with usual care, women who received the DA had reduced DC (β = -1.51; 
95% CI; -2.54 to 0.48; P = 0.031), after adjusting for education, desire for children 
and baseline uncertainty. The sub-scale scores of the DCS were examined in two of 
these three studies and results varied as to where the greatest and most consistent 
benefits from DAs were observed. After adjusting for confounding or influential 
variables, Berry and colleagues (2013) reported significantly reduced DC over time 
for the subscales of uncertainty, -3.61 units (95% CI, -7.01 to -0.22) (p = 0.04) and 
values clarity, -3.57 units (95% CI, -5.85 to -1.30) (p = 0.002), but not among the 
informed, support or effective decision subscales. Jibaba-Weiss and colleagues (2011) 
also reported that DA participants had scores indicating that they were significantly 
clearer about their personal values related to the decision regarding breast cancer 
surgery than controls. The authors reported the greatest difference on the ‘informed’ 
subscale, where the DA group reported being more informed about surgical options 
and related risks (p = 0.007). Indeed, none of the women in the DA group were unsure 
about their surgery choice, while 10.5% of the controls were. All three studies were 
methodologically strong, thus increasing confidence in the results relating to 
reductions in DC post-DA exposure. 
 
The fourth controlled study assessing DC reported no intervention effect on the DCS 
total scale, but did find a significant group effect on the ‘informed’ subscale, 
indicating that the DA group felt better informed after exposure to the DA 
(Vodermaier et al, 2009). However, the study noted that a strong culture of shared 
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decision-making between clinicians and patients existed in the study centre, such that 
all patients experience a high degree of participation in treatment decision-making. 
This could explain why the DA had little impact on DA-exposed versus non-DA 
exposed patients’ DC scores. Two of the four trials measured the longer-term effect 
(12 months follow-up) of DAs on total DC. Statistically significant group differences 
were maintained for participants in one study (Peate et al, 2012) but group differences 
were not apparent after the same time period in the other study (Jibaba-Weiss et al, 
2011).  
 
Of the remaining two studies assessing DC, Davidson and colleagues (2007) 
compared a generic versus individualized DA and Feldman-Stewart and colleagues 
(2012) compared a DA to an identical one that included an additional explicit values-
clarification exercise. Neither study reported significant differences between groups at 
either baseline or post-DA exposure. However, significant decreases in DC were 
reported for all participants following use of their respective DAs in both studies over 
time. Both studies were considered in the current review to be of good 
methodological quality. However, results in the Davidson et al (2007) study are only 
generalizable to newly diagnosed prostate cancer patients who want access to 
additional information and decision support after their treatment consultation. In the 
Feldman et al (2012) study, only 37% of potentially eligible patients in two of the 
participating clinics took part in the study, with the majority approached declining on 
the basis of not experiencing any decisional conflict related to their treatment 






This study systematically reviewed the literature in order to investigate the 
effectiveness of cancer treatment-related decision aids at improving patient 
knowledge and reducing DC. Despite the variability in cancer diagnoses, decisions 
and measurement, the studies found that DAs were successful in improving patient 
knowledge about treatment options and outcomes and reducing their DC. 
Consequently, the findings of the current study are consistent with other reviews of 
DAs in a broader health treatment context and in cancer-related care (Neuman et al, 
2007; Waljee et al, 2007; O’Connor et al, 2009). However, as only one DA was made 
available by the authors of the included studies for review (Peate et al, 2012), 
variation and comparisons relating to the quality of the DAs used could not be 
commented upon.  
 
Overall, the studies included in this review found a positive effect for DAs in 
improving patients’ treatment-related knowledge, suggesting that patients who use 
DAs generally feel more informed about their treatment options. The finding of 
higher treatment-related knowledge scores among DA-exposed participants in the 
controlled studies suggests that the usual consultation method for health professionals 
used to inform patients about various treatment options and possible outcomes for 
these complex decisions may not be good enough, where evidence suggests that little 
of the imparted clinical information is retained (Lavelle-Jones et al, 1993; Lloyd et al, 
1999). Patients need to fully understand the information in order to make an informed 
decision. Thus, the results of the reviewed studies appear to support previous research 
suggesting that reinforcement of verbal information with written or visual material 
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may enhance patient knowledge and understanding about cancer treatment options 
(Neuman et al, 2007; Spiegle et al, 2013). However, use of non-validated scales for 
assessing the knowledge effect both highlights the need for more robust measures to 
be developed or for researchers to test the validity and reliability of self-developed 
tools. This issue was also highlighted by Spiegle and colleagues (2013) in their recent 
systematic review of cancer treatment decision support interventions, where all but 
one study used non-validated knowledge scales. Whilst knowledge is among the most 
common outcome variables used to assess DA effectiveness, few studies have 
explicitly described how knowledge items on measures used were generated, 
reviewed or tested (Smith et al, 2012). Thus, the overall results relating to treatment-
related knowledge in the current review must be interpreted with caution. 
 
The post-DA reduced scores for total DC and for most DC subscales across studies 
indicate and provide support for the argument that DAs help patients to feel more 
comfortable with their treatment choices (O’Connor et al, 2009; Stacey et al, 2014). 
Participants receiving the DA in the controlled studies had less DC than participants 
who did not use such a tool (Brown et al, 2012), providing further support for the 
implementation of DAs into usual care. However, some limitations of these studies 
should be considered. A lack of significant differences between DA-exposed versus 
control groups in the controlled trials on some of the DCS subscales was noted.  This 
may be due to the fact that all four controlled studies assessing DC highlighted the 
fact that participating clinics had active patient education programmes/decision 
support as part of standard care (Collins et al, 2009; Jibaba-Weiss et al, 2009; 
Vodermaier et al, 2009; Feldman-Stewart et al, 2012). Therefore, it not surprising that 
DC scores fell for all participants in these studies if a high level of decisional support 
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was already in place. This may not be representative of usual care control groups in 
other controlled trials assessing the effectiveness of DAs in reducing treatment-related 
decisional conflict. Additionally, Davidson and colleagues (2007) only recruited men 
who had requested additional information about their treatment above the usual 
amount, thus limiting the generalizability of their findings to the wider prostate cancer 
treatment population. The response rate of less than 40% in two of the participating 
centres that kept eligibility statistics also affects generalizability of the study findings 
(Davidson et al, 2007).  
 
Strengths of the review 
 
Unlike many other systematic reviews, a strength of this review was the decision to 
broaden the inclusion criteria to include all studies (and not RCTs alone) in order to 
increase the likelihood of a more comprehensive review of available DAs for cancer 
treatment. The potential for subjective bias in methodological analysis was also 
reduced as two-thirds of the included articles were independently rated with regard to 
methodological quality. The study did not exclude any articles based on language 
from the initial search and the search was not limited to DAs developed in Western 
countries. 
 
Limitations of the review 
 
Only one researcher carried out searches and selection of final papers, whereas the 
project would have benefitted from two or more researchers taking part in every stage 
of the review process but unfortunately, due to limited resources, this was not 
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possible. Despite the widespread use of knowledge and DC as outcomes in 
effectiveness of DA trials, few studies have determined baseline measures prior to DA 
exposure. In order to ensure that the effectiveness of the DA in reducing DC and 
and/or increasing treatment-related knowledge was directly resulting from exposure to 
the DA itself, the decision was made for the current study to exclude nine studies 
without such baseline measures. This rigid inclusion criterion could be considered as 
a potential limitation as it limits the ability to place the statistically significant 
reductions in DC found in the current review in the context of previous studies.  
 
Implications for research  
 
One of the main questions to arise from this review is, ‘What measure of knowledge 
should be employed to evaluate decision aid effectiveness?’ There is definite scope 
for more validated tools to be developed by researchers. There also appears to be a 
paucity of tools available to measure DC in health-related decision-making. Whilst 
the DCS has been shown to be a valid and reliable research instrument for measuring 
DC (O’Connor et al, 2010), a potential limitation of the scale is the lack of 
comparative measures. Thus, further validation work is required to enhance the 
psychometric properties of the scale, particularly in terms of its construct and content 
validity. Additionally, the limited number of cancer types included in the review 
highlights the need for treatment- related DAs for other cancer diagnoses to be 
developed for appropriate preference-sensitive decisions. A more general next step for 
decision aid research would be the comparison of different types of decision aids to 
determine which features actually impact upon decision-making for patients. Such 
research would help developers to achieve the most effective DA design possible. 
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Overall, further research is necessary to solidify the evidence base concerning the 
impact of DAs on cancer treatment-related knowledge and DC, and the link between 
these and other relevant outcomes.  
 
Implications for clinical practice 
 
On a practical level, the main implication is that DAs should be used to help patients 
make difficult cancer-related treatment choices. Treatment-related DAs are already 
being incorporated into clinical practice in the NHS and this review provides support 
for their continued implemention in cancer-related care. Improvements in patient 
knowledge and reductions in DC regarding treatment-related decisions accord with 
the aim of the NHS (Department of Health, 2012): to implement a SDM model and to 
enable patients to make informed choices. Thus, from the perspective of 




Treatment decisions are likely to increase in complexity with the arrival of new 
technologies and treatment options. Consequently, the need to inform and educate 
patients properly becomes predominant. This review has systematically examined the 
existing literature evaluating the effectiveness of patient DAs for improving 
knowledge and reducing DC in treatment-related cancer decisions. The available 
evidence indicates that DAs are better than usual care in improving patients’ 
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Background: This study explored the decision-making processes of ovarian cancer 
patients who had decided for or against CA-125 testing during post-treatment 
surveillance, in order to assess the need for a decision aid.  
 
Methods: Semi-structured interviews were conducted with 18 women in an 
outpatient gynecological oncology clinic in Scotland. Transcripts were analysed 
thematically using the ‘Framework’ approach. 
 
Results: Accurate knowledge about CA-125 testing in post-treatment surveillance 
was found to greatly influence participants’ decision-making processes. Most women 
with less knowledge about the test chose to have testing based on the false belief that 
earlier detection of recurrence would lead to earlier treatment and prolonged survival. 
Women who placed importance on the CA-125 test during the diagnostic and 
treatment stages appeared more likely to opt for testing post-treatment. CA-125-
related anxiety was present for women opting to have testing. However, among the 
participants still in remission, this anxiety was outweighed by the perceived 
reassurance provided by testing.  
 
Conclusion: Clinicians must ensure that patients are fully informed about the pros 
and cons of CA-125 testing in post-treatment surveillance and be aware of individual 
values and preferences among women surrounding this decision. The need for a 
decision aid to ensure accurate knowledge about CA-125 and to aid decision-making 
for women was confirmed. 
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Keywords: CA-125 testing, ovarian cancer, oncology, decision-making, decision aid, 
qualitative, post-treatment surveillance, follow-up  
 








Ovarian cancer is the leading cause of death amongst gynecological malignances 
(Marcus et al, 2014). Despite an encouraging response from primary treatment, 70-
80% of patients with advanced disease (stages III or IV) will relapse within the first 
two years (Martin & Schilder, 2009). Unfortunately, as full remission is rarely 
possible, treatment following relapse of ovarian cancer is palliative (Ledermann & 
Raja, 2011). Post-treatment surveillance for ovarian cancer is standard practice in 
Europe and the United States (Verheijen et al, 2012), and follow-up care typically 
includes cancer antigen 125 (CA-125) serum testing (Bast et al, 1981). CA-125 is a 
protein found in the blood, commonly referred to as a “tumour-marker” due to its 
ability to provide information about the biological state of ovarian cancer (Tiller et al, 
2003). It is elevated in over 80% of women with advanced epithelial ovarian cancer 
(Goonewardene et al, 2007). However, high CA-125 levels are not specific for 
ovarian cancer and can be elevated under various conditions, and false-positive 
elevations can occur (Cannistra, 2004).  
 
Elevated CA-125 levels are known to accurately predict recurrent disease on average 
five months before symptom development (Rustin et al, 2010). While it is widely 
accepted that patients with a rising CA-125 level and physical symptoms should 
commence treatment, a debate is ongoing regarding whether asymptomatic women 
with rising CA-125 levels alone should be treated, and indeed, whether or not CA-125 
monitoring should be a routine part of post-treatment surveillance (Markman, 2003; 
Rustin, 2013). Results of the recent multinational European trial (MRC 
OVO5/EORTC 55955) studying the role of CA-125 in post-treatment surveillance has 
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challenged accepted practice of routine CA-125 testing (Rustin et al, 2010). The trial 
concluded that there was no survival benefit from early treatment performed on the 
basis of an elevated CA-125 level alone in asymptomatic women. This finding lends 
support to the results from recent systematic reviews where none of the identified 
studies supported a survival benefit from hospital-based follow-up treatment after 
completion of primary treatment for ovarian cancer (Lajer et al, 2010; Geurts et al, 
2011). Additionally, trial participants randomly allocated to the early-treatment trial 
arm suffered from higher levels of anxiety and a lower quality of life than women 
whose treatment was delayed until physical symptoms of recurrence presented. As a 
result of this trial, international guidelines (Verheijen et al, 2012; Society of 
Gynecologic Oncologists, 2013) recommend that the role of CA-125 and the 
advantages and limitations of routine monitoring should be discussed with patients in 
order to aid the decision-making process. 
 
Studies have highlighted the unrealistic expectations that many women have about the 
role and impact of the CA-125 test in terms of survival (Doyle et al, 2001; Palmer et 
al, 2006; Harrison et al, 2009; Oskay-Oezcelik et al, 2009) and the small amount of 
research in this area suggests that patient knowledge about the test and its significance 
in post-treatment surveillance is limited (Parker et al, 2006; Reid et al, 2011). 
Notably, it has been highlighted that women with lower levels of knowledge about 
CA-125 can be more preoccupied with it, which in turn is associated with lower mood 
(Parker et al, 2006) and higher levels of anxiety. Anxiety surrounding CA-125 testing 
has been reported in several studies researching follow-up care for ovarian cancer 
(Hipkins et al, 2004; Parker et al, 2006; Matulonis et al, 2008; Mirabeau-Beale et al, 
2009; Oskay-Oezcelik et al, 2009; Reid et al, 2011). Patients may initially opt for 
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regular testing due to their feelings of fear and uncertainty in the post-treatment 
period and loss of their safety net of intensive professional monitoring (Hipkins et al, 
2004; Lydon et al, 2009). However, research evidence suggests that this decision can 
lead to patient preoccupation with the CA-125 level (Harries & Gore, 2002; Palmer et 
al, 2006; Coupe et al, 2010; Jordens et al, 2010) and rising CA-125 levels have been 
reported to trigger panic, profound fear and devastation that the cancer has recurred 
(Guidozzi, 1993; Howell et al, 2003). Alternatively, fear of recurrence has been noted 
as ovarian cancer patients’ greatest concern (Wenzel et al, 2002; Matulonis et al, 
2008; Lewis et al, 2009; Dahl et al, 2013) and studies have found that the reassurance 
provided by regular CA-125 testing can alleviate anxiety surrounding a possible 
recurrence for some women (Bradley et al, 1999; Jordens et al, 2010). Many women 
also find reassurance in being as fully informed as possible about their disease status 
and information is viewed positively (Bradley et al, 1999). Thus, individual factors 
and the potential impact of CA-125 monitoring on quality of life should be a serious 
consideration for women in their decision-making process. 
 
The Present Study 
 
The decision about regular CA-125 testing in post-treatment surveillance for ovarian 
cancer is a preference-sensitive decision for patients. The goal of making a 
preference-sensitive decision is to make a ‘‘quality’’ decision rather than the ‘‘right’’ 
decision, based on being fully informed and consistent with the individual’s values 
(Ropka et al, 2006). Despite the central role CA-125 currently plays in the monitoring 
for recurrence of ovarian cancer, few studies have set out to explore women’s 
decision-making processes surrounding the option to have CA-125 testing in post-
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treatment surveillance. Thus, the aim of the current study was to explore the decision-
making processes of ovarian cancer patients who had opted for or against CA-125 







Following ethical approval, participants were recruited from a National Health 
Service (NHS) outpatient gynecological oncology clinic within a city-based Scottish 
healthcare trust. Potential participants were identified by their Consultant Oncologist, 
informed about the study during a routine consultation, and given a study information 
pack containing an information leaflet, consent form and stamped-addressed envelope 
for use if they wished to participate. Following receipt of the returned consent forms, 
author FEW contacted potential participants by telephone. Eligible participants had a 
diagnosis of epithelial ovarian cancer of any stage, had completed first-line treatment 
and were a minimum of six months post-decision making about CA-125 testing at the 
time of recruitment. Women deemed to be significantly cognitively impaired by their 
consultant were not approached, as informed consent was a necessary prerequisite for 
participation. Ten women who had chosen to have regular testing (mean age = 62.6 
years; range = 45-74 years) and eight women who had decided against it (mean age = 
61.12 years, range = 49-76 years) were recruited between September 2012 and 
October 2013. As most women choose to have regular CA-125 testing, it had been 





Consenting participants were interviewed at a time and date of their convenience in a 
private room at the outpatient clinic or in their home. Author F.E.W conducted all 18 
in-depth, semi-structured interviews (mean = 40 min; range = 25 – 60 mins). The 
authors developed a semi-structured interview schedule for the purposes of the study. 
In order to assess participants’ knowledge about CA-125 testing, the women were 
presented with a patient vignette regarding a slight rise in a woman’s CA-125 level 
and asked to choose what they perceived to be the most likely scenario occurring. As 
shown in Figure 2, option 4 is the correct answer out of the five options provided. 
Interviews were digitally recorded and transcribed verbatim for analysis.  
 
Figure 2. Patient scenario vignette 
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Data Analysis  
 
The framework approach was adopted in order to provide a structured and transparent 
method to approach data analysis (Ritchie & Lewis, 2003; Smith & Firth, 2011). The 
utility of framework analysis within healthcare research has become increasingly 
recognised in recent years (Smith & Firth, 2011), and it is deemed particularly useful 
when considering practice-related questions. Framework analysis is differentiated 
from other qualitative data analysis techniques in that as well as encouraging themes 
to emerge inductively, it often starts deductively from the pre-determined aims and 
objectives of the research (Pope et al, 2000). As the study sought to explore some 
broad pre-determined topics (including CA-125 related knowledge, the CA-125 
decision-making process and CA-125-related anxiety) in order to inform future 
development of a decision aid it was deemed a desirable approach to adopt. Analysis 
involved moving through a number of stages (see Table 5) and was aided by using 
QSR NVivo 10 qualitative data analysis (QSR International, 2012) to help organise 





Table 5. Framework analysis procedure 
       Stage Steps Taken 
Stage 1  Familiarisation with the interviews 
The lead researcher read and re-read each transcript to 
become familiar with the whole data set. 
Stage 2 Initial Coding Independent initial coding of six randomly selected transcripts by two researchers. 
Stage 3 Developing a working analytical framework 
Researchers met following independent coding to agree on a 
set of codes to apply to all subsequent transcripts, forming 
the initial analytical framework. 
Stage 4 Applying the analytical framework 
Following completion of coding of the remaining transcripts 
using the initial analytical framework, the framework was 
revised to incorporate new and refined codes.  
Stage 5 Charting data into the framework matrix 
Following completion of coding using the final analytical 
framework, the data was summarized in a matrix using 
Microsoft Excel. 
Stage 6 Interpreting the data 
Themes were generated from the data set by reviewing the 
matrix and making connections within and between 





For the purposes of this article, Testing Group will refer to the participants having 
regular CA-125 testing and Non-Testing Group will refer to those who decided 
against it. Five overarching themes emerged from analysis of the data and are outlined 
below: knowledge about CA-125 testing; the CA-125 decision-making process; CA-
125-related anxiety; reassurance; and false beliefs about earlier detection of cancer 





Table 6. Final coding index or analytical framework 
Themes Sub-Themes 
Knowledge about 
CA125 testing  
! General knowledge about CA-125 testing 
! Impact of diagnosis and treatment on information 
retention during consultations  
CA125 Decision-
Making Process 
! Personal significance of CA-125 testing at diagnosis and 
during treatment 
! Time taken to decide 
! Additional decisional support sought 
! Personality factors 
CA125-Related 
Anxiety 
! Anxiety in the 10-day test period 
! Strategies to cope with CA-125 testing-related anxiety 
! Worry in general about CA-125 count 
! Informing loved ones about the decision 
Reassurance 
• General feeling of reassurance with testing  
• Reassurance versus anxiety 
• Fear of cancer recurrence 
• Reassurance provided by health professionals 
False beliefs about 
earlier detection of 
cancer recurrence  
! Unrealistic expectations despite knowledge about 
delaying treatment until physical symptoms show  
 
 
Knowledge about CA125 testing 
 
General Knowledge About CA-125 Testing 
 
Participants were asked about their knowledge of the CA-125 test and its function 
during post-treatment surveillance. Apart from the knowledge that the CA-125 test 
was a blood test, the majority of participants in the Testing Group appeared to have 
little understanding about the test and its function during post-treatment surveillance, 
and only half of the group chose the correct scenario from the patient vignette (see 
Figure 2). Those who had answered incorrectly selected option 3, surmising that the 
!
! 53 
patient’s cancer had returned and that she had a better chance of being cured because 
the recurrence had been spotted early. Participants in this group reported receiving 
varying degrees of information about CA-125 testing from their oncologists, with 
only two participants recalling any information given about the pros and cons of 
testing or surrounding the fragility of the test in terms of accurately diagnosing 
disease recurrence. As one participant stated: 
 
‘A lot of information on CA-125 testing is not something I specifically remember but it might 
have just been one thing in amongst a whole load of things to take in. I may well have been 
told about it in more detail? If you don’t have any medical experience the information that all 
the medics are giving to you is a lot!’ (P2) 
 
In contrast, participants in the Non-Testing Group had greater knowledge about CA-
125 testing in follow-up care and had discussed both the fragility of the test and the 
OV05 trial results with their oncologist. Indeed, seven of the eight participants in this 
group cited the trial evidence as the main influencing factor over their decision to 
decide against regular testing: 
 
‘Based on the OV05 trial that it wasn’t going to make a huge amount of difference with an 
early diagnosis and start of treatment if there was a recurrence or not’ (P8) 
 
 ‘I think the fact that it wasn’t totally necessary and that it didn’t always give a proper reading 
for people as well and you would know with other ways. And I think as Dr [name] had said 
that it [the test] maybe helps to find it [cancer recurrence] sooner but it didn’t make that much 
difference in the treatment whether they discovered it sooner or later. So I thought that it 




Of note, these seven participants also correctly identified the most likely scenario 
within the patient vignette.  
 
Impact of Diagnosis & Treatment on Information Retention During Consultations 
 
Analysis within cases across both testing groups revealed that participants who had 
admitted to having little knowledge about CA-125 testing had commented upon the 
emotional impact of the diagnosis and/or treatment on their ability to retain 
information during clinical consultations. As these two participants described: 
 
‘When I got diagnosed, I was kind of shocked at how big the cyst was that they found and 
that I hadn’t realized that I had it! And you often go in [to a consultation] and you have so 
many questions and sometimes someone will respond to that question. And that answer will 
be the thing that you remember from the whole [conversation], everything else goes. You 
don’t remember all of the other stuff’ (P6, Testing Group) 
 
‘My daughter-in-law would remember all of this better than me because I got all agitated the 
first time you know? She [Consultant] said that there was a small bit of the cancer that they 
couldn’t remove and that I couldn’t have radiation because they couldn’t get to it. And of 
course I got upset and I was concentrating so much on that that I really can’t remember much 
else or much about the blood test?’ (P1, Non-Testing Group) 
 
The CA-125 Decision Making Process 
 




Most participants in the Testing Group commented upon the significance of the CA-
125 test both in the initial detection of their cancer and during their treatment phase 
when discussing their rationale for their decision. As the following women noted: 
 
‘Well as far as I understand it, before I had treatment it was all about diagnosis. And it was 
the CA-125 count that made everybody move very quickly! Then came chemotherapy, then 
surgery, then more chemotherapy. Before each lot of chemotherapy, the week before there 
was a CA-125 blood test. And that showed dramatic drops once the chemotherapy had 
started.’ (P3) 
 
‘I think it’s interesting if you ask women how much they know about CA-125 before the 
diagnosis with ovarian cancer. But it’s one of the things that you’re told in the very 
beginning. It’s sits there, this CA-125. That it’s a tumour marker and it’s up. But we’re 
aiming to get it with chemotherapy. So, it is a feature, a big feature, of the treatment you 
know?’ (P7) 
 
This sub-theme did not emerge within the interviews with participants in the Non-
Testing group.  
 
Time Taken to Decide 
 
Results revealed that only one woman in the Testing Group took time to deliberate on 





‘I made it on the spot.  I just thought well why not? It’s just a blood test! It wasn’t a big deal. 
I just told Dr [name] to go ahead with it’. (P10) 
 
‘Well I said yes straight away. I’d rather meet something head on. I think the decision for me, 
a blood test, it’s not as if they were digging into you to find something. I thought it was an 
easy thing to know, a reassuring thing.’ (P5) 
 
In contrast, only a few participants in the Non-Testing Group made the decision 
during the consultation session, with the majority choosing to take the three months 
offered before their next consultation to decide: 
 
‘I certainly remember going away thinking that I must think about this, it was a big decision 
(P7) 
 
‘I did take my time. And I decided for the following check-up which was in another three 
months that I wouldn’t have it’ (P9) 
 
Additional Decisional Support Sought 
 
Results were varied regarding participants’ need to consult loved ones to aid decision-
making, with some participants involving family members and others choosing to 
decide alone. Participants who made their decision on the spot were less likely to 
consult others than those who took more time to deliberate. The majority of 
participants in both groups did not seek additional information about CA-125 testing 




‘I’m not a kind of person for reading books on anything like that. I believe in just taking 
whatever comes and dealing with it at the time. Otherwise you look up the internet, you look 
up books, you’ll end up killing yourself with worry rather than the cancer getting you! So, 
I’m not a believer in that’ (P5) 
 
The participants who did seek out information on CA-125 testing on the internet or in 
educational pamphlets on ovarian cancer did not feel that doing so had had a major 




An interesting finding regarding the decision-making process related to the 
participants’ perceptions of the influence of personality factors on their decision-
making regarding testing. As one participant described: 
 
‘It all depends on your personality and the type of person you are. An awful lot’s to do with 
your, and it can be a burden to you, but to do with your personality. It does help with 
decision-making for me.’ (P4) 
 
A comparison of the two groups regarding personality factors found that participants 
in the Testing Group stated the need to be fully informed about all aspects of their 
care, despite the fact that women in this group were found to have lower levels of 
knowledge about CA-125 testing: 
 




‘All along I’ve been told exactly what was happening which was what I wanted. I wanted to 
know everything that was happening to me.’ (P14) 
 
In contrast, members of the Non-Testing Group admitted to basing their decision 
either on the fact that they would actually be more anxious if they were having 
testing, or the fact that they wanted to maintain a positive outlook for the future:  
 
‘I guess in a way part of it was getting yourself stressed out for no reason. I think I’m sure if I 
got the test and it [the result] was slightly up on the last one I probably would worry. And also 
because I’m aware that it’s not always 100% accurate and I didn’t want to go getting myself 
all hyped up and worried for nothing.’ (P17) 
 
‘I think for me, I don’t think testing that would be helpful. Because the way I look at it, I’m 
feeling great, I’m carrying on with my life as normal. And if I can do that, then that’s what I 




Anxiety in the 10-Day Test Period 
 
Participants who had chosen to have CA-125 testing described their experiences of 
anxiety surrounding the test. Most participants in the Testing Group reported 
experiencing anxiety in the 10-day waiting period between having the blood test and 




‘How could it not? If you said to anybody, you’ve got to go to court tomorrow, they would 
start fretting! Even if they were a witness! And it is that sort of position you’re in with the 
test, it’s not great.’ (P4) 
 
Strategies to Cope with CA-125 Testing-Related Anxiety 
 
These participants discussed various coping strategies used to deal with this anxiety, 
with many contacting their GP a few days prior to their oncology consultation to 
obtain the result. As one participant outlined: 
 
‘I worked out a system of getting the blood test done the Thursday before clinic and called for 
the result Friday to have time to digest the result before seeing the consultant the following 
week. To me that works well and allows me time and a little bit of space before my 
appointment’ (P12) 
 
Worry in General About the CA-125 Count 
 
The only participants who described worrying about their CA-125 level outside of 
this 10-day waiting period were the only two women that had experienced relapsed 
disease. Both individuals commented upon the psychological impact of detecting 
recurrence via CA-125 testing and the impact of testing on their quality of life:  
 
‘I suppose if someone could prepare you for the psychological difficulty that you get when 
the count is starting to go up. Because up until then you think you’re the one that got away 
and you feel, well, you’re going to be cured and that awful thing’s gone and then it’s apparent 
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that it hasn’t and that it’s spread around through your blood to other bits. And it’s the CA-125 
test that shows this up.’ (P3) 
 
‘It has impacted upon my quality of life because now every three months you’re having your 
possible life examined and foreshortened and brought into question. And you can build 
yourself up and build yourself up and get so anxious about the result that you sometimes can’t 
see a way out. When it first started to come back [CA-125 level rising] I was a wreck. I was 
really was all over the place mentally. I couldn’t stop crying, you know?’ (P12)  
 
Informing Loved Ones About the Decision 
 
A further sub-theme emerging from the data relating to CA-125 anxiety surrounded 
the decision by many of the participants within the Testing Group to not inform their 
loved ones that they were having regular testing. These participants stated that they 
had made this decision in order to protect their loved ones from experiencing anxiety 
about the test result. Family members of the participants who had been informed 





The theme of reassurance emerged within both groups.  
 




Within the Testing Group, this predominantly related to the perceived reassurance 
provided by regular CA-125 testing and the feeling of safety resulting from post-
treatment surveillance:  
 
‘Well basically, it’s a very strange thing but when you have chemotherapy, for all it’s 
nastiness and the side-effects are horrible, you kind of feel safe. Because, you know that 
they’re [doctors] watching it and something is trying to kill this horrible thing. When that 
stops, you feel vulnerable and once anybody’s been told that they’ve got cancer, it’s on your 
shoulder all the time. It’s like being stalked, it never goes away. So when you stop the chemo 
and you’re feeling vulnerable, you’re looking for something else you see because you’re 
frightened that as soon as you stop the chemo, it’s going to come back. So you’re looking for 
something to spot it.’ (P3) 
 
Reassurance Versus Anxiety 
 
The participants in the Testing Group who had not experienced relapsed disease and 
who had reported experiencing CA-125-related anxiety all commented upon the 
reassurance of testing out-weighing their anxiety. As one woman described: 
 
‘And the blood test, for all it destroys your peace of mind, sometimes it gives you peace of 
mind as well. Because you know that they’re going to pick it up and do something for you if 
they can’ (P4) 
 
Some of these women had even requested or were planning to request more frequent 




‘I’ve six month check-ups now. But then I spoke to my own GP and she asked me if I was 
okay with this and I said, “Well, I would have preferred every three months but I suppose 
you’ve got to move on.” And she very kindly does it every three months for me." (P5) 
 
‘I think that I’d be happier if I had one [a CA-125 test] every wee while. Even when the five 
year surveillance programme’s over. Even if it’s just once a year.’ (P4) 
 
Fear of Cancer Recurrence 
 
Fear of cancer recurrence was a recurring sub-theme for this group and many women 
commented on the usefulness of the test in reassuring them that cancer had not 
recurred:  
 
‘I just thought, “Well, if there’s a test that we can do that helps monitor something other than 
just, “I feel a bit this way or I feel a bit that way”, then for me it felt like it was at a more 
cellular level. Because you do think about the cancer all the time. That doesn’t go away’ (P6) 
 
‘The fact that I feel great means nothing. There’s nights that I don’t sleep that well. I feel tired 
and I think, “Am I tired because the cancer’s back or am I just tired?” So you’re constantly 
reviewing things and the CA-125 helps in that respect’ (P15) 
 
Reassurance Provided by Health Professionals 
 
Of note, the sub-theme of fear of recurrence did not emerge within the Non-Testing 
group. However, many women spoke about the reassurance they received from their 
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oncology team and the trust placed on their Consultant Oncologist to provide them 
with accurate information to aid their decision-making about CA-125 testing: 
 
‘I did tend to go by what he [Oncologist] said because he's an expert and obviously dealing 
with this day in day out! He always puts me at ease!’ (P17) 
 
‘I was aware that she [Oncologist] wasn’t pushing it [CA-125 testing] and I thought, “Well if 
she doesn’t think that it’s that important then it can’t be that important. I mean I’m trusting! 
I’m assuming that they are doing the best for me. I’ve no reason to doubt that because they’ve 
been fabulous. But, no I thought well if she’s not putting a huge importance on it then it’s not 
important. And if it’s not important then, heck, I’ve got life to get on with!’(P18) 
 
False Beliefs About Earlier Detection of Cancer Recurrence 
 
Within the Testing Group, an additional theme of note emerged from the data, where 
most women referred to a belief that earlier detection of recurrence with CA-125 
testing would lead to earlier treatment and prolonged survival.  
 
‘I feel that it’s another, sort of, indicator that things are looking good. And if there was an 
increase then it could be a wee early warning that things were not so good. And then you 
would, you know, get treatment for that earlier than if you waited for other signs’ (P2) 
 
‘I just felt that I wanted this thing controlled and so if there’s anything that’s going to pin-
point it starting back again, the sooner it’s caught the better. The sooner they find it, the 
sooner they can start treating it. I mean that’s all you want is for somebody to treat it. Keep it 




‘What I felt was at least if someone was tracking it, the treatment would be appropriate at the 
appropriate time. And that if I left it and waited for how many years I don’t know, maybe I’ll 
miss the boat.’ (P12) 
 
This was despite an acknowledgement by some of being informed by their oncologist 
of the reasons why immediate treatment would not commence upon detection of a rise 
in CA-125 level alone: 
 
‘I was told that if it started to go up and it meant that the cancer had come back, that it 
wouldn’t be curable but that it would be treatable. But I thought that if I did, if it started to 
creep up then the doctors would know and surely do something about it and stem the disease 
if they could. So, I thought, okay, you know, best monitor it and any treatment if it’s treatable 
would get it as soon as you can to prolong your life hopefully.’ (P5) 
 
‘I believe that with this blood test being done, if they spot anything early, I know they don’t 
always jump in and do chemotherapy straight away because they don’t know really when to 
start it, but I think it gives them a better idea of what’s going on. And if it rises any higher up 
they can maybe look further into it. I just thought, well the quicker you [health professionals] 
know, the better for me’ (P10) 
 
Importantly, these women identified this belief as the main influencing factor for their 








This qualitative study sought to gain a greater understanding of the decision-making 
process surrounding CA-125 testing in post-treatment surveillance among ovarian 
cancer patients, in order to assess the need for a decision aid for women making this 
decision in real-time. To our knowledge, this was the first study to carry out such 
work among ovarian cancer patients.  
 
The results indicate that accurate knowledge about the CA-125 test in follow-up care 
appears to greatly influence participants’ decision-making processes. Women in the 
Non-Testing Group had a much greater understanding about the fragility of the test 
and the fact that a detected rise in CA-125 would not initiate immediate second-line 
treatment, than those in the Testing Group. This knowledge base was the main 
deciding factor for the majority of women in this group, suggesting that such an 
understanding provided them with the confidence to make an informed decision based 
upon their preferences and values. In contrast, the majority of participants in the 
Testing Group had limited knowledge about CA-125 testing and based their decision 
on the expectation that a raised level would lead to immediate treatment and 
prolonged survival. These results appear to support the Conflict Theory of Decision-
Making (Janis & Mann, 1977), which suggests that a ‘vigilant’ coping style leads to 
careful information seeking and deliberation, whereas ‘unconflicted adherence’ or 
alternatively, ‘hypervigilance’ are maladaptive and associated with unproductive 
information-seeking and decision-making patterns. The latter finding also adds to the 
body of research highlighting the discord between patient expectations and realistic 
treatment scenarios (Doyle et al, 2001; Palmer et al, 2006; Harrison et al, 2009; 
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Oskay-Oezcelik et al, 2009). Overall, the results from this group highlight the need 
for health professionals to be aware of the potential emotional impact of a diagnosis 
and/or treatment on patients’ abilities to retain information during consultations, a 
finding commonly described elsewhere (Fallowfield & Jenkins, 1999). Thus, it is 
recommended that health professionals ensure that patients fully comprehend the pros 
and cons of CA-125 testing and the OV05 trial results. The results of the current study 
surrounding the influence of accurate knowledge on decision-making provide support 
for the development of a decision aid to assist health professionals in ensuring that 
this is achieved.  
 
Regarding the decision-making process itself, it was interesting to note that 
individuals who had mentioned the significance of CA-125 testing at the point of 
diagnosis and/or during treatment all chose to continue testing in follow-up care. This 
may indicate that patients who choose testing generalize the information about CA-
125 testing at these earlier stages to post-treatment surveillance, where it is perceived 
that continuing testing may have treatment benefits for recurrence in the absence of 
other symptoms. This may have been a factor in why these individuals made a 
decision quite quickly, needing less deliberation time than participants in the Non-
Testing Group. It may also be linked to the continued need for these individuals to 
feel in control. This was in contrast to the Non-Testing Group participants who felt 
that having testing would be more likely to cause them anxiety. The influence of 
personality factors and personal values in patient’s decision-making should not be 
underestimated. As decision aids are designed to take these important factors into 
account, these findings provide additional support for a decision aid where clear 
information would be introduced post-treatment to ensure that women are fully 
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informed about the unlikely commencement of treatment for possible recurrence 
based on a rising CA-125 count alone. As there was a notable contrast between 
women making the decision either in the consultation or waiting three months, a 
decision aid would also encourage women who decide on the spot to give the decision 
further consideration to reduce the chance of experiencing decisional regret at a later 
date.  
 
Similar to other studies, CA-125-related anxiety was experienced by many of the 
participants who had chosen to have regular testing (Hipkins et al, 2004; Parker et al, 
2006; Oskay-Oezcelik et al, 2009; Anderson et al, 2011). It cannot be discounted that 
women with an anxious predisposition may be more likely to opt for CA-125 testing. 
As reported elsewhere it would appear that this anxiety was accepted and endured as a 
result of the perceived feeling of reassurance and safety provided by the test (Bradley 
et al, 1999). However, it is likely that once this feeling of reassurance has been taken 
away with the knowledge of rising CA-125 levels, patients experience panic and fear 
about the recurrence (Harrison et al, 2009) and the fact that second-line treatment is 
unlikely to commence without physical symptoms present (Jordens et al, 2010). This 
probability was supported by the current study findings, whereby the two participants 
who had experienced anxiety more generally, and reported a negative impact of 
testing on their quality of life, were the only participants who had experienced 
relapsed disease. Given the high statistical chance of recurrence with ovarian cancer, 
it is not surprising that fear of recurrence is the greatest concern for patients (Wenzel 
et al, 2002; Matulonis et al, 2008; Lewis et al, 2009; Dahl et al, 2013), yet it is 
essential that those choosing to have regular testing are fully informed about the pros 
and cons of that particular decision. Patients would also greatly benefit from more 
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research focused on investigating the psychological impact of CA125 testing, 
particularly among women with relapsed disease whose recurrence was detected via a 
rising CA125 count. Such research would help facilitate the provision of targeted 
psychological support for this group coping with relapsed disease.  
 
There were some limitations to this study that should be acknowledged, including its 
small sample, which may not provide results that can be generalised to a larger 
population. Data saturation was sought where recruitment stopped at the point at 
which no new themes emerged. However, it is impossible to preclude the possibility 
that had further interviews been conducted, new themes might have arisen. Thus, 
whilst the interviews with participants provided a range and richness of data on the 
topic of interest, there are likely to be other perspectives that exist, which would 
extend the range of views that have been gathered in this study. Additionally, the fact 
that only women in the Testing Group were asked about CA125-related anxiety is 
another limitation, as this may be the reason why a fear of recurrence was not raised 




In conclusion, more emphasis has now been placed on shared decision-making and 
patient choice surrounding the use of CA-125 testing for post-treatment surveillance. 
The importance placed on shared decision-making for this medical scenario has 
highlighted a gap in the literature for a decision aid to assist women during this 
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Background: The aim of the current study was to elicit patient and health 
professionals’ views on the proposed development of a patient decision aid aimed at 
helping women to decide for or against CA-125 testing during post-treatment 
surveillance for ovarian cancer.  
 
Methods: Semi-structured, in-depth interviews were conducted with ovarian cancer 
patients (n  = 18) and health professionals (n = 6) in an outpatient gynecological 
oncology clinic in Scotland. Transcribed data were analysed using the Framework 
approach.  
 
Results: There was strong enthusiasm for the development of the proposed decision 
aid to assist women facing this treatment decision in real time. The preferred setting 
for use of the decision aid was the home environment but views were mixed about the 
timing of decision aid delivery to patients. Regarding decision aid content, patients 
regarded personal stories surrounding the decision as a helpful addition.  
 
Conclusion: Women would benefit from the use of a decision aid when considering 
CA-125 testing during post-treatment surveillance for ovarian cancer. As well as 
assisting women with this decision, the proposed decision aid may ultimately support 
health professionals in practicing shared decision-making regarding CA-125 testing 




Keywords: Decision-making, decision aid, ovarian cancer, post-treatment 
surveillance, follow-up, CA-125 testing, qualitative 
 
 





Cancer-antigen 125 (CA-125) testing has played an important role in both the 
diagnosis and treatment of ovarian cancer (Pignata et al, 2011). However, controversy 
surrounds the use of CA-125 testing in post-treatment surveillance for the disease 
(Chitale, 2009; Pignata et al, 2011; Morris & Monk, 2010). CA-125 is a blood 
protein, commonly referred to as a ‘tumour-marker’ due to its ability to provide 
information about the biological state of ovarian cancer (Tiller et al, 2003). It is 
elevated in over 80% of women with advanced epithelial ovarian cancer 
(Goonewardene et al, 2007) and elevated CA-125 levels are known to accurately 
predict recurrent disease on average five months before symptom development 
(Rustin et al, 2010). While it is widely accepted that patients with a rising CA-125 
level and physical symptoms of recurrence should commence treatment, a debate is 
ongoing about whether asymptomatic women with rising CA-125 levels alone should 
be treated, and indeed, whether or not CA-125 monitoring should be a routine part of 
post-treatment surveillance at all (Markman, 2003; Pignata et al, 2011; Rustin, 2013). 
 
Post-treatment surveillance is based on the assumption that patients will benefit if 
recurrent disease is treated early (Jordens et al, 2010). The recent multinational 
European trial (MRC OVO5/EORTC 55955) studying the role of CA-125 in post-
treatment surveillance has challenged this assumption, as the trial concluded that there 
was no survival benefit from early treatment performed on the basis of an elevated 
CA-125 level alone in asymptomatic women. As a result of this trial, it is now 
advocated that the decision surrounding CA-125 testing in post-treatment surveillance 
should rest with the patient and that the advantages and limitations of routine 
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monitoring should be discussed with patients (Verheijen et al, 2012; Society of 
Gynecologic Oncologists, 2013). Patient education and involvement in medical 
decision-making is widely considered to be very important (O’Connor et al, 2009). 
This is particularly relevant in the case of preference-sensitive decision-making. A 
preference-sensitive decision in one where the decision requires weighing patients’ 
values for benefits and risks across options, including the option of doing nothing, in 
order to achieve a higher quality decision (Stacey et al, 2008). Such decisions are 
common considerations for cancer patients (Sepucha et al, 2007).  
  
Over the past few decades, significant advancements have been made to improve 
patients’ ability to make cancer-related treatment decisions (Whelan et al, 2004; 
Waljee et al, 2007; O’Brien et al, 2009, O’Connor et al, 2009; Spiegle et al, 2013). 
The development of decision aids (DAs) is one such advancement. DAs differ from 
traditional health educational materials by providing a detailed and balanced 
description about available options, and the risks and benefits of each option using 
explicit probabilities to outline them (Sawka et al, 1998; O’Connor et al, 2007). A 
systematic review of DAs has shown that, compared with controls, patients receiving 
DAs had higher knowledge, lower decisional conflict, more active participation in 
decision-making and lower decisional regret post-intervention (O’Connor et al, 2009). 
DAs exist for women at risk of ovarian cancer (Tiller et al, 2003), and as an aid for 
asymptomatic women with rising CA-125 levels regarding decisions for second-line 
treatment (Anderson et al, 2011). However, the Cochrane Registry of DAs contains 
no DAs developed to assist women faced with the decision of having regular CA-125 




It is strongly recommended that both clinicians and patients be involved in the DA 
development process (Informed Medical Decisions Foundation; IMDF, 2014; 
International Patient Decision Aids Standards Collaboration; IPDAS, 2014; Ottawa 
Decision Support Framework; ODSF, 2014). Stage one of this process should involve 
information gathering on preferences, knowledge, and attitudes surrounding the 
decision to be made (ODSF, 2014). DA content is crucial when examining the 
informational preferences and needs of cancer patients, including a balanced view of a 
range of possible options open to patients (O’Connor et al, 2009). For example, 
whether DAs should include personal stories about individuals in similar situations 
who have already gone through the decision-making process is currently being 
explored and debated (Khangura et al, 2008; Winterbottom et al, 2008; Bekker et al, 
2013). Following the results of the aforementioned European trial, Rustin (2011) 
argued that women should be provided with three options surrounding CA-125 testing 
during post-treatment surveillance for ovarian cancer  (see Tables 1 & 2). Whether or 
not the addition of the third option would be useful to patients, or health professionals 
(HPs) in charge of their care, has not yet been explored.  
 
Thus, the decision surrounding regular CA-125 testing during post-treatment 
surveillance is a preference-sensitive one for the majority of ovarian cancer patients. 
As a result of the OV05 trial, more emphasis has now been placed on individual 
patient choice, and the importance placed on shared decision-making (SDM) for this 
medical scenario has highlighted a gap in the literature for a DA to assist women 





The Present Study  
 
The goal of this study was to elicit patient and HPs’ views on the proposed 
development of a patient DA designed for ovarian cancer patients surrounding the 
decision to have CA-125 testing during post-treatment surveillance in order to 
identify important factors to consider in the development of such a tool. A qualitative 
approach was adopted in order to capture participants’ views on pre-determined 
questions, whilst also allowing for the emergence of issues or concerns that had not 






The Ottawa Decision Support Framework (ODSF) guided the study design for the 
development of the proposed DA, which emphasizes a three-step process of 
development (ODSF, 2014). According to the ODSF (2014), the first step involves 
the need to assess patient and clinician determinants of decisions to identify decision 
support needs. The current study reports results from the second part of the needs 
assessment interviews conducted with ovarian cancer patients who had already gone 
through the decision-making process surrounding CA-125 testing. Detailed results 
from the first part of these interviews have been described elsewhere (Wilson et al, 
thesis submission). HPs were also recruited to consult on the development of the 
proposed DA. In addition to design-related questions, HPs were asked their opinion 
regarding the advantages and disadvantages of CA-125 testing for women entering 
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post-treatment surveillance. It was deemed important to gain from their professional 
knowledge and clinical experience in order to ensure accurate content of the pros and 






Potential participants were identified by their Consultant Oncologist, informed about 
the study during a routine consultation, and given a study information pack containing 
an information leaflet, consent form and stamped-addressed envelope for use if they 
wished to participate. Following receipt of the returned consent forms, author FEW 
contacted potential participants by telephone. Eligible participants had a diagnosis of 
epithelial ovarian cancer of any stage, had completed first-line treatment and were a 
minimum of six months post-decision making about CA-125 testing at the time of 
recruitment. Women deemed to be significantly cognitively impaired by their 
consultant were not approached, as informed consent was a necessary prerequisite for 
participation. The study aimed to gain a balanced perspective from patients who had 
decided for and against regular CA-125 testing. Consequently, ten women who had 
chosen to have regular testing (mean age = 62.6 years; range = 45-74 years) and eight 
women who had decided against it (mean age = 61.12 years, range = 49-76 years) 
were recruited between September 2012 and October 2013. All 18 participants also 
consented to being contacted following the development of the proposed decision aid 





Health Professional Sample 
 
Health Professional (HP) participants were recruited from the gynecological oncology 
team at the same outpatient clinic as patient participants. The sample consisted of 
three Consultant Oncologists and three clinical nurse specialists (CNSs). All six 
individuals had extensive experience in providing professional decisional support to 
ovarian cancer patients surrounding the decision to have CA-125 testing or not in 




As part of the interview and in order to ensure that both patients and HPs had an 
understanding of what a DA was, participants were shown an example of an existing 
DA which was the closest example available on the subject of CA-125 testing 
(Anderson et al, 2011). Participants were also shown an information sheet outlining 
the pros and cons of each of the three options proposed by Rustin (see Tables 7 & 8), 
in order to ensure that they fully understood the implications of these options. The 
information sheet was developed using simple, everyday language.  
 
 




Option 1 To have routine CA-125 measurements prior to each clinic visit where both the patient and oncologist are aware of the results 
Option 2 Not to have routine CA-125 measurements provided that the patient is well and has no symptoms suggesting relapse 




Table 8. Overview of possible CA-125 testing options 
Option A 
To have CA-125 test prior to each clinic visit and both you and your doctor know the result 
POSSIBLE BENEFITS POSSIBLE DOWNSIDES 
Reassuring when good (i.e. not rising) Anxiety around waiting for the result and anxiety if 
rising 
If blood test is rising, it allows you and doctor to plan 
treatment ahead of time  
Anxiety of knowing cancer is coming back, if this 
happens, around 5 months earlier (on average) than 
before you would have done with other options 
Allows you more warning to plan your life around 
knowing when you might be back on treatment if the 
cancer recurs 
Does not tell you or your doctor when to start treatment 
Allows entry into research trials based on rising blood 
test with no symptoms  
Does not improve the cure rate or the length or quality 
of overall survival 
Allows possible treatment with hormone tablets if 
your tumour is ER (estrogen receptor) positive.  These 
take time to work 
Involves an extra visit to the GP for a blood test prior 
to clinic and an extra needle 
Lets you and your doctor know to watch for 
symptoms of relapse if CA-125 starts to rise 
False reassurance if cancer is relapsing without blood 
test rising (not common) 
Option B 
Not to have CA-125 test unless new symptoms develop 
POSSIBLE BENEFITS POSSIBLE DOWNSIDES 
No anxiety around waiting for the result and anxiety if 
rising 
Lack of reassurance 
No extra visit to the GP for a blood test prior to clinic 
and an extra needle 
May miss out on the opportunity to use hormone 
therapy if ER positive tumour 
No chance of false reassurance if cancer is relapsing 
without blood test rising (not common) 
Does not allow entry into research trials based on rising 
blood test with no symptoms 
Around 5 months extra (on average) of living well 
without knowledge of cancer coming back if this 
happens 
Less time to plan treatment if cancer comes back 
You and your doctor focussing on quality of life only   
Option C 
To have CA-125 test prior to each clinic visit but only your doctor knows the result 
POSSIBLE BENEFITS POSSIBLE DOWNSIDES 
No anxiety around waiting for the result and anxiety if 
rising 
Lack of reassurance 
You and your doctor focussing on quality of life only No chance of false reassurance if cancer is relapsing 
without blood test rising (not common) 
Around 5 months extra (on average) of living well 
without knowledge of cancer coming back if this 
happens 
Extra visit to the GP for a blood test prior to clinic and 
an extra needle 
Doctor can advise you on the opportunity of entry into 
research trials based on rising blood test with no 
symptoms if this happens 
Anxiety that doctor knows something you do not and 
that may create issues for you both 
Doctor can advise you on the opportunity to use 
hormone therapy if ER positive tumour if suitable 
Less time to plan treatment together if cancer comes 
back 





Following ethical approval from the local Research Ethics Committee, participants 
were recruited from a Scottish National Health Service (NHS) outpatient 
gynecological oncology clinic within a city-based health board trust. Consenting 
patient participants were interviewed at a time and date of their convenience in a 
private room at the outpatient clinic or in their home. Author FEW conducted all 24 
in-depth, semi-structured interviews (mean = 45 min; range = 25 – 65 mins). 
Interviews were digitally recorded with the participants’ consent, anonymised and 




The framework approach was adopted for data analysis (Ritchie & Lewis, 2003). The 
utility of this method within healthcare research has become increasingly recognized 
in recent years (Smith & Firth, 2011) and it is deemed particularly useful when 
considering practice-related questions. Framework analysis is differentiated from 
other qualitative data analysis techniques in that as well as encouraging themes to 
emerge inductively, it often starts deductively from the pre-determined aims and 
objectives of the research (Pope et al, 2000). As the current study sought to explore 
some pre-determined topics in order to inform future development of a decision aid it 
was deemed a desirable approach to adopt. Analysis involved moving through a 
number of stages (Ritchie & Lewis, 2003) (see Table 9) and was aided by using QSR 
NVivo 10 qualitative data analysis (QSR International, 2012) to help organise and 




Table 9. Framework analysis procedure 





The lead researcher read and re-read each transcript to become 
familiar with the whole data set. 
Stage 
2 Initial Coding 
Independent initial coding of eight randomly selected 
transcripts by two researchers. 
Stage 
3 
Developing a working 
analytical framework 
Researchers met following independent coding to agree on a 
set of codes to apply to all subsequent transcripts, forming the 
initial analytical framework. 
Stage 
4 
Applying the analytical 
framework 
Following completion of coding of the remaining transcripts 
using the initial analytical framework, the framework was 
revised to incorporate new and refined codes.  
Stage 
5 
Charting data into the 
framework matrix 
Following completion of coding using the final analytical 
framework, the data was summarized in a matrix using 
Microsoft Excel. 
Stage 
6 Interpreting the data 
Themes were generated from the data set by reviewing the 
matrix and making connections within and between 




For the purposes of this article, Testing Group will refer to the participants having 
regular CA-125 testing and Non-Testing Group will refer to those who decided 
against it. Five overarching themes emerged from analysis of the data and are outlined 
below: usefulness of the DA in the decision-making process; including patient stories; 
DA setting; DA timing; and the preferred choice of options. 
 
Usefulness of the DA in the Decision-Making Process 
Patient Perspectives 
 
All patient participants felt that a DA would be very useful for women who were 
making the decision in real-time and proposed a number of reasons why. Many 
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participants felt that a DA would reduce the chance of experiencing decisional 
conflict and regret: 
 
‘Because it wasn’t so much of an informed decision in the beginning for me, it was a gut 
reaction. If you had something like that [DA], you’d be much more confident that you’ve 
made the right decision for you.’ (P3, Testing Group) 
 
‘I have to say that I’ve always wondered if I hadn’t made that decision what it would have 
been like. So if I’d gone through that process [with a DA], maybe I wouldn’t have that 
question? Or maybe I’d still have that question but go back to my decision aid and say, ‘Why 
did I write that?’ So, having that tool might have erase that question.’ (P12, Testing Group) 
 
‘I would have found that quite useful because I’m feeling now that I made a rash decision. I 
just made the decision within a minute of being asked really which probably in hindsight 
wasn’t ideal. I think if they’d [HPs] said, “Take this [DA] away and read it and let us know 
what you think”, it would have been a lot better.’ (P18, Non-Testing Group) 
 
Patients also highlighted the importance for women of feeling a sense of 
empowerment and control over their decision-making, and stated that having such a 
tool would provide women with the ability to do this. As one patient commented: 
 
‘It’s important that you’re in control of the decision. So having something like that [DA] 
would help to reinforce that feeling’ (P4, Testing Group) 
 
Patients also reflected upon the difficulty that they had experienced making the 
decision regarding CA-125 testing during the post-treatment period due to fatigue and 




‘I think at the time you’ve got to make the decision, your head’s not in it. You’re just saying 
to them [the doctors], “Whatever you think, whatever you think” and you don’t really know 
what you’re entering into? You’re just so tired by that point. So having that tool would be so 
useful.’ (P4, Testing Group) 
 
‘It would be so helpful because that’s the most vulnerable time at the end of treatment. If you 
don’t have any medical experience the information that all the medics are giving to you is a 
lot! I wish I had had that [DA] when I had to decide!’ (P12, Testing Group) 
 
Finally, one patient commented upon the fact that a DA would ensure that all ovarian 
cancer patients are getting the same information from their oncology team:  
 
‘It means that everyone is getting the same information. You know what I mean? Because 
some doctors will say this and some doctors will say that but if you give them that booklet 




All six HPs stated that the proposed DA would be an extremely helpful tool for 
encouraging SDM: 
 
‘I think that it would be so helpful. I think that with patients with ovarian cancer, their future 
is so uncertain that they almost feel that they don’t have control over their own life. But to 





‘Actually, just even going through it with the patients like that in a written down format might 
make it easier. Because we do explain to them their options when we have this discussion but 
it’s probably at the end of quite a long consultation and they may not take it in.’ (HP5) 
 
‘I think it’s all about instead of having patient leaflets, having things that help people to make 
the right choices for them. So I just think this is really the way to go! I’ve done many, many 
patient leaflets in my time and they are, by their very nature, paternalistic. They’re very hard 
to involve people in. They’re not a discussion.’ (HP6) 
 
HP participants discussed their perceptions surrounding the advantages and 
disadvantages of CA-125 testing for women. Advantages highlighted included: the 
ability for women to make future plans following detection of suspected relapsed 
disease; the possible option of entering into clinical trials; and a perceived sense of 
reassurance from testing. However, all six HPs regarded the main disadvantage of 
testing to be the anxiety that it created for women and commented on how fixated 
patients could get about the CA-125 count itself: 
 
‘I think that a lot of patients get really focused on the number and what the number means. 
And they get so focused on the number that they forget about living their life. So 
psychologically it’s quite damaging’ (HP2) 
 
‘There’s certainly a sizeable cohort of individuals who get totally fixated on their CA-125. 
And when they come in to see you they’re not really interested in telling you how they’re 




This anxiety was hypothesised to result from a lack of understanding about the 
purpose of CA-125 testing in follow-up care, and HPs highlighted the usefulness of a 
DA to improve patient knowledge. As one participant described:  
 
‘I think it’s because they [patients] don’t understand enough about it. When patients start to 
become obsessed with their CA-125 count I usually try to sit them down and explain what a 
CA-125 means and why we do it. Sometimes that does help but I almost think it’s too late 
because they’ve already got it in their head that the actual number is the most important thing. 
So I don’t know whether they actually take in what you’ve said to them? So having a DA 
would be really helpful in those scenarios to ensure that they do understand the facts, and I 
suspect would actually reduce the levels of anxiety that we see in clinic’ (HP1) 
 
Including Patient Stories 
 
Patient participants were asked whether having had access to knowledge of other 
women’s stories about the decision-making process surrounding CA-125 testing 
would have been helpful during their own decision-making, and if the inclusion of 
such stories in the proposed DA would be a useful addition. Views were mixed as to 
the personal impact of having access to these stories on their own decision-making, 
with the majority reporting that access to these accounts would have been helpful but 
some individuals pointing out how personal the experience of having cancer is: 
 
‘Well I would have read about it and seen what other women said but I think at the end of it 
there’s only one person who can really make up your mind and that’s yourself. I mean it’s 
like listening to other people about childbirth. It’s not the same for everybody. So, I think 
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you’ve got to decide what’s best for yourself, what you feel about things.’ (P5, Testing 
Group) 
 
Despite varied opinions given, all patient participants advocated for stories to be 
included in the proposed DA for a number of reasons. Many participants felt that it 
would provide the option for women to engage in the material or not and that it would 
be helpful in providing a more balanced view of the decision options. Moreover, it 
was considered a helpful addition for someone who was experiencing decisional 
conflict:  
 
‘When it’s difficult to make decisions sometimes we feel confused and it’s difficult to work 
out what’s right for you. So, sometimes it’s good just having that, well, “This is the process 
that I went through and now I’m here and I feel that I made the right decision”, or “I made the 
wrong decision and this is why I think it was the wrong decision”. So yeah, I think it would 
be helpful’ (P6, Testing Group) 
 
For those women who did not report experiencing decisional conflict, it was still 
deemed useful to include stories in order to understand the reasoning behind 
individuals who chose the opposite option to their own one. As one woman who opted 
to have CA-125 testing explained: 
 
‘I think it might have been helpful to hear from the other side because the women who walk 
away [opt against regular testing], we never hear about how they’ve got on? And why they 
opted out of it? So yes, I think it would have helped to have a few stories about various 




Other participants felt that including stories could provide a feeling of reassurance for 
some women: 
 
‘Just knowing that you’re not the only one to go through the decision-making process. You 
tend to think that it’s just you but you know perfectly well that it’s not.’ (P14, Testing Group)  
 
Some participants hypothesised that having other women’s stories available in the DA 
would provide a similar feeling of reassurance as the one gained from reading patient 
stories on internet blogs:  
 
‘I think that people need a lot of reassurance. When people look up the internet and hear from 
other people, “Well this is normal and that’s normal,” it’s comforting.’ (P4, Testing Group) 
 
‘Yeah I think everyone’s different and has different responses, but I follow some of the 
websites and with some of the women I say, “Yeah, I totally agree with that. That’s really 
helpful’, but with others I think, ‘Nah, I disagree with you.” But it’s helpful to read both sides 






The overwhelming majority of patients felt that the DA should be given to patients to 
take home to use and to return to their next consultation with any further questions 
that they may have. The main reason stated for this preference was the need to take 




‘It would be good to take it home and you could really absorb it, you can read it again and 
look at it quietly. So, I think a bit of information beforehand, then get this [DA] and if you’ve 
got any immediate questions you could ask them and then take it away and really absorb the 
information.’ (P2, Testing Group) 
 
‘In some ways I’m leaning towards taking it away and being able to sit at home and read it 
through how ever many times you need. Then possibly coming back to see your consultant 
and discussing what you’ve decided.’ (P13, Non-Testing Group) 
 
Some patients felt that completing the DA during their oncology consultation might 
feel a bit overwhelming and impact upon decision-making:   
 
‘I think it might be a wee bit more upsetting sitting talking to an oncologist about it because 
it’s kind of like a final decision thing isn’t it? I think that you need time to digest it all.’ (P5, 
Testing Group) 
 
‘I think if you had it at home you would have time to think about it. Rather than a doctor 
breathing down your neck as you’re going through it because then it would be totally your 
own opinion.’ (P16, Non-Testing Group) 
 
‘I think that you should have time to read it by yourself or with someone else at home and 
really think about it because sometimes yes-or-no decisions can be difficult. And it doesn’t 
always reflect how you’ll feel all the time. So you need to let it seep in a wee bit. The need to 







Similar to patient participants, the consensus among HPs was that it would be 
preferable for women to take the DA home in order to go through it at their own pace: 
‘Perhaps a brief outline in the clinic and then to give it to them to take home so they could 






The optimal time for introduction of the DA for patients emerged from the analysis 
and views were mixed. Some patients stated that the DA would be most valuable at 
the end of treatment: 
 
‘I think that the best time to do it is after you’ve had your last chemo, your last scan and you 
come for the results of what the whole treatment plan has done for you. That’s the time to do 
it.’ (P3, Testing Group) 
 
However, the majority indicated that the most appropriate time would be at the first 
follow-up appointment with the oncologist, and where patients would have a three-







Two HPs stated that post-treatment might be an overwhelming time to receive the DA 
and that prior to treatment would be of most value. As one HP commented: 
 
‘It might be too late when they’ve finished treatment because what I’m thinking is that to get 
someone to sit and read that in-depth, you’ve got to get them at a time when they’re taking on 
what’s happening with them. You know when someone is first diagnosed, they’re right onto 
everything. When they’re finished treatment, a lot of them really don’t want to know about 
what’s happening next.’ (HP3) 
 
However, the remaining four HPs considered the first follow-up consultation as being 
the most appropriate time, when the discussion surrounding CA-125 testing usually 
took place. 
 




While some women felt that a choice of the three proposed options should be 
included (see Tables 7 & 8), the majority of patients thought that the DA should only 
include the two more straightforward options of either choosing to have or to not have 
CA-125 testing in follow-up care. Inclusion of the third option was considered 
unhelpful by patients because of the potential for it to create unnecessary anxiety and 




‘I can’t really think what advantage there is in option C? I think that you would just 
constantly worry. You’d be analysing the doctor and if she were off with you, you’d be 
thinking, “Is she a little bit worried?” It would make me personally fret more with that one I 
have to say!’ (P3, Testing Group) 
 
‘I can’t understand why a patient would come after having the blood’s done and sit there and 
not be curious? It’s only human nature! You would sit and look at that doctor and think, “Do 
you know something that I don’t?” I think you could put yourself into a worrying state. 
Personally, I would think that if Dr [name] was sitting with some information and I didn’t 
know about it I would have myself worked up for the next 3 months until I get the bloods 





In the HP group, the three CNSs felt that the third option should be included in order 
to provide patients with the reassurance that they were being monitored, and to 
capture the preference of the minority of patients who preferred a more paternalistic-
style of relationship with their oncologist. As one CNS described: 
 
‘I think option C might be useful because I suppose it gives the person the option of not 
knowing until they need to know so that they can carry on with their life. But it would give 
them the reassurance that someone’s monitoring them. I also think that there’s probably a 
group of patients that falls under the category of, “The doctor knows best so, I’ll just let him 




However, the three oncologists were very opposed to the idea both for practical 
reasons and due to a feeling of discomfort about the ‘paternalistic nature’ of the 
option: 
 
‘No, because I think that you could get into a difficult situation with that option. Because you 
know but the patient doesn’t know and you probably need to tell the GP but they’d need to be 
clear that they can’t tell the patient. But, I suppose if the patient asks them [the GP] they’ll tell 
them. So I think with option C you’d have to be careful because that might become more of 
an issue than it is already.’ (HP4) 
 
‘No, because it creates a scenario where you’re potentially not telling the patient everything 
which makes me feel uncomfortable. It makes me feel that the patient-doctor relationship is 
altered and it goes back to the old days where patients didn’t expect the doctor to tell them 
anything. We certainly like to help patients think that we’re telling them everything and so I 




The aim of this qualitative study was to elicit patient and HP opinions on the proposed 
development of a DA for women contemplating CA-125 post-treatment monitoring 
for ovarian cancer. The proposed DA would, to our knowledge, be the first DA to 
assist women in deciding for or against CA-125 testing. Overall, our findings indicate 
a high general interest and positive appraisal by ovarian cancer patients and HPs for 
the proposed DA. Indeed, all 24 participants were extremely positive about the 
potential role of this tool in a woman’s decision-making process regarding CA-125 
testing, particularly in reducing the risk of experiencing decisional conflict and regret 
!
! 99 
and promoting more active participation. Therefore, these findings provide further 
support for the benefit of DAs among individuals facing cancer-related treatment 
decisions (e.g. Whelan et al, 2004; Spiegle et al, 2013). Highlighting CA-125-related 
anxiety, HPs also considered it to be a useful tool to have during consultations, in 
order to increase patient knowledge about the pros and cons of the decision, as 
advocated by relevant international bodies (Verheijen et al, 2012; Society of 
Gynecologic Oncologists, 2013).  
 
There was a general perception that the proposed DA would encourage SDM during 
consultations between patients and HPs. Participants reflected upon the difficulties 
that women have with decision-making in the post-treatment phase, and hypothesized 
that a DA would be help patients to feel a sense of empowerment and control over 
their decision-making and assist HPs with effective communication. The positive 
impact of clinical decision support systems to improve clinical practice has been 
evidenced previously (Kawamoto et al, 2005). Thus, it is likely that the proposed DA 
would provide a framework that enables SDM, leading to increased confidence in 
decision-making for both parties.  
 
Despite the ongoing debate about the inclusion of patient’s personal stories in DAs 
within the literature (e.g. Khangura et al, 2008; Winterbottom et al, 2008), all patient 
participants in the current study were enthusiastic about their inclusion in the 
proposed DA. Whilst it was acknowledged as not being personally useful to some, 
importance was placed on offering the choice to women to engage in the material or 
not in order to help reduce any decisional conflict and to provide reassurance. With 
respect to location of use, the majority of participants suggested that the DA should be 
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given to use at home, in order to give patients the opportunity to work through the 
material in their own time. However, there was some debate about the ideal timing for 
patients to receive and use the DA. While the majority viewed the first follow-up 
appointment as the most appropriate time, others were of the opinion that this may be 
too late for some women. Consideration of the most appropriate time to introduce a 
DA is important, being mindful of introducing it too soon and possibly overwhelming 
a patient or waiting too long and missing the opportunity to assist with decision-
making. These results suggest that DA timing in the care pathway may affect the 
usefulness of the tool to patients. Therefore, it is suggested that HPs gauge the correct 
time based on their knowledge of the patient and her informational needs. Overall, the 
results have highlighted the fact that timing is an issue requiring further investigation 
during the piloting phase of the proposed tool. 
 
An important consideration for the content of the proposed DA was the inclusion or 
exclusion of the third option for patients proposed by Rustin (2011), which involved 
having CA-125 testing but not being informed about the results. The value of 
adopting a qualitative approach in the current study to investigate this question was 
evident by the reasons elaborated upon by the majority of participants for their 
recommendation to exclude the third option. It was particularly interesting to note the 
split in opinion between the CNSs and the oncologists in the HP sample, with the 
former advocating for inclusion of the third option and the latter strongly opposed. 
Whilst it is impossible to make any proper conclusions or assumptions from such a 
small number of participants, it raises the question as to whether the direct 
professional role of a HP in the CA-125 decision-making scenario impacts upon their 
view regarding this debate. In the current study setting, the discussion surrounding 
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CA-125 testing is usually introduced to patients by their oncologist during a 
consultation, with the CNSs providing additional decisional support if necessary out-
with these discussions. Therefore, one questions whether the experience of being 
directly, versus indirectly, involved in the SDM scenario influences professional 
opinion on the inclusion of the more paternalistic third option?  Further research with 
a larger sample of HPs is suggested to explore their perspectives on this issue. 
 
Limitations of the study included the limited generalisability of the findings due to a 
small sample size and the fact that the study was conducted at a single location, which 
makes it unlikely to be representative of follow-up services offered on a national or 
international basis for women with ovarian cancer. Additionally, the opinions 
provided by participants surrounded a hypothetical DA that they did not have in 
person to evaluate. Therefore, it will be important to confirm these views with 





Our findings emphasise the usefulness of decision support tools to aid decision-
making in cancer care, and the importance of clinician and patient involvement in the 
DA development process (IMDF, 2014; IPDAS Collaboration, 2014; ODSF, 2014). 
The results illustrate that a proposed patient DA for women deciding about regular 
CA-125 testing during routine post-treatment surveillance for ovarian cancer would 
be considered to be an appropriate and important tool to assist patients with this 
preference-sensitive decision. The proposed DA may ultimately support HPs in 
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practicing SDM regarding this decision with ovarian cancer patients.  Participant 
opinions on the exclusion of the third option regarding CA-125 testing is likely to be 
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wherever possible be original papers rather than reviews. Exhaustive lists should be 
avoided. Citation of conference proceedings or meeting abstracts should also be 
avoided unless there is no other reference. 
References in the text should be made by giving, in brackets, the author's surname, 
with the year of publication. 
When the reference is to a specific part of a book, the page number should also be 
cited. When reference is made to a work by three or more authors, the first name 
followed by et al, should be used for all citations in the text (Weiss et al, 2001). If 
several papers by the same first author and from the same year are cited, a, b, c, etc, 
should be added after the year of publication. Authors are asked to check the accuracy 
of all references before submitting a manuscript. References should be brought 
together at the end of the paper in alphabetical order, where titles of papers and all 
authors' names should be given in full. 
Names of journals should be abbreviated as in Index Medicus, followed by the 
volume number and the initial and final page numbers, e.g.: 
Nagai H, Pineau P, Tiollais P, Buendia MA, Dejean A (1997) Comprehensive 
allelotyping of hepatocellular carcinoma. Oncogene 14: 2927 - 2933 
Wherever possible, include the digital object identifier (DOI), from the article's title 
page. Please note the following example: 
Nanduri and Zimniak P (1999) Arch Biochem Biophys 362: 167 - 174, 
doi:10.1054/abbi.1998.1009 
References to books and monographs should appear as in the following examples: 
Means JH (1984) The Thyroid and its Diseases. Lippincott: Philadelphia 
Stevenson AC (1966) Sex chromatin and sex ratio in man. In Sex Chromatin, Moore 
A. (ed) pp 405 - 425. W. B. Saunders: Philadelphia 
 
Figures 
Figures and images should be labelled sequentially, numbered and cited in the text. 
Figure legends should be printed, double spaced, on a separate sheet titled 'Titles and 
legends to figures'. Figures should be referred to specifically in the text of the paper 
but should not be embedded within the text. The use of three-dimensional and 
shadowed histograms is strongly discouraged when the addition of the third 
dimension gives no extra information. If a table or figure has been published before, 
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the authors must obtain written permission to reproduce the material in both print and 
electronic formats from the copyright owner and submit it with the manuscript. This 
follows for quotes, illustrations and other materials taken from previously published 
works not in the public domain. The original source should be cited in the figure 
caption or table footnote. (see Permissions) 
 
Artwork Guidelines 
A detailed guide to preparing artwork for submission can be downloaded at 
http://www.nature.com/aj/artworkguidelines.pdf. Please submit production quality 
artwork with your initial online submission. If your paper is accepted for publication 
and you have followed the Guide to Preparing Artwork, it will not be necessary to 
resubmit the artwork following the peer-review process, unless changes are required 
by the reviewers or our Editor. 
 
Colour in print 
Full colour illustrations may be included in the printed text, at the discretion of the 
editor. However, a charge may be made to the author to cover the extra costs incurred 
in originating and printing colour illustrations. It is helpful if authors who submit 
colour figures indicate in their covering letter whether they are willing, in principle, to 
meet these costs. Prior to publication, authors will be advised of the costs, which 
depend on the size and quantity of colour illustrations. 
 
Colour online 
We are usually able to substitute colour versions of illustrations in the HTML version 
of the online journal at no additional cost. The online PDF of the paper exactly 
matches the printed journal and will therefore carry the black and white version of the 
figure, as printed. Authors wishing to take advantage of this facility are asked to 
submit a 300 dpi black and white and a colour file for the electronically published 
version. Please refer to the Guide to Preparing Artwork. 
 
Tables 
Tables should only be used to present essential data. Each must be on a separate sheet 
with a title or caption and be clearly labelled, sequentially. Please make sure each 
table is cited within the text and in the correct order, e.g. (Table 3). 
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Tables should ideally be presented in Excel, one table per workbook. It is imperative 
that the tables are editable. Please save the files with extensions .xls / .xlsx / .ods / or 
.doc or .docx. Please ensure that you provide a 'flat' file, with single values in each 
cell with no macros or links to other workbooks or worksheets and no calculations or 
functions. 
BJC has recently changed its style for tables. Please consult some of the papers 
published in Volume 108 (2013) for examples of the current layouts and follow one 
of those as closely as possible. 
 
Supplementary online material 
Authors wishing to provide additional material supporting their paper, may wish to 
have this published online as supplementary material linked to the paper on the BJC 
website. 
All supplementary materials must be submitted with the original manuscript and will 
be shown to referees. This allows papers to have greater depth, online enhancements, 
such as video clips and additional data sets, making them more useful to fellow 
specialists in the field who require detail, without distracting more general readers. 
Authors should ensure that supplementary information is supplied in its FINAL 
format because it is not subedited and will appear online exactly as submitted. It 
cannot be altered, nor can new supplementary information be added, after the paper 
has been accepted for publication. All supplementary material must be cited in the 





Appendix 2. Systematic Review Protocol 
 
 
Outline of the review question 
 
Title: Are decision aids for cancer treatment-related decisions effective at increasing 
treatment-related knowledge and reducing decisional conflict? A systematic review. 
 
Aim: To evaluate the effectiveness of treatment-related decision aids at increasing 
knowledge and reducing decisional conflict in cancer patients.  
 
Rationale for the systematic review 
 
A search of the Cochrane Database of Abstracts of Reviews and Effects (DARE) 
identified four articles that were related to the proposed systematic review: 
 
1. Molenaar et al (2000) - a systematic review on the feasibility and effects of 
DAs 
2. Stacey et al (2014) - a systematic review on DAs for health treatment or 
screening decisions.  
3. O’Brien et al (2002) - a systematic review on the impact of cancer-related 
DAs 
4. O’Brien et al (2009) - a systematic review and meta-analysis of the 
effectiveness of cancer-related DAs in screening, prevention and treatment 
(most closely linked to the proposed study)* 
 
*Limitations of the O’Brien et al (2009) study (CRD Review): 
" Only RCTs where randomization was used for allocation to 
experimental and control groups were included. Thus, no attempts to 
identify unpublished data. 
" Search terms were not reported and publication bias was not 
considered in the report.  
!
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" Validity was assessed using established criteria, but results of the 
assessment were not reported, which made it difficult to assess 
reliability of the evidence presented. 
" Only 5 out of the 34 trials included in the study were related to 
treatment and the authors identified the need for further research to 
determine the effectiveness of decision aids in the treatment context. 
 
A recently published article focusing on treatment-related decision support 
interventions for cancer was identified during a Google Scholar search (Spiegle et al, 
2013). The objective of the study was to identify alternative types of decision support 
interventions (DSIs) for cancer treatment and a meta-analysis to compare the 
effectiveness of these DSIs to decision aids. Overall, no significant differences in 
knowledge, anxiety, satisfaction or decisional conflict scores between DAs and other 
DSIs were found.  
 
However, the study had a number of limitations: 
" Only published studies using a RCT design were included 
" Only studies based on treatment decision-making for breast, lung, prostate and 
colorectal cancer were included. 
" Only included decision aids that were evaluated relevant to standard/usual 
care and not alternative interventions.  
 
Decision aid definition 
 
Decision Aid definition for this review:  
 
DAs are tools that help patients become involved in decision making by making 
explicit the decision that needs to be made, providing information about the options 
and outcomes, and by clarifying personal values using values clarification exercises 









• Quantitative studies evaluating a decision aid for adult patients with a 
histologically proven cancer diagnosis facing a choice related to treatment  
• Studies which include measures of treatment-related knowledge and/or 
decisional conflict pre and post a decision aid intervention  




• Studies where full text articles can not be sourced either as a complete 
published article or by contacting the authors directly for complete 
unpublished drafts 
 
Outcomes of Interest 
 
• Patient knowledge of treatment options 
• Decisional conflict 
 
Planned search strategy 
 




• Cumulative Index to Nursing and Allied Health Literature (CINAHL) 
• Sociological Abstracts 
• Cochrane Library 
• PsychInfo 
 
(b) Reference lists of published systematic reviews of decision aids  
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(c) Reference lists of full text articles considered for inclusion 
(d) Hand search of the following journals from 2009-2014: Medical Decision Making, 
Patient Education & Counseling, Journal of Clinical Oncology, BMC Medical 
Informatics & Decision Making.  
 
Planned search terms (following a consultation with a University of Edinburgh 
Librarian) 
 
• Decision aid 
• Decision support technique* 
• Decision support system* 
• Decision tool 
• Education* aid 





Planned data extraction methods 
 
Data will be extracted using a pre-designed form. A single reviewer will extract all 
the data, and a second reviewer will independently check the completed data 
extraction forms for accuracy and completeness. 
 
Data will be collected on: 
• first author, year of publication, country,  
• cancer diagnosis,  
• types of treatment options available to participants,  
• study design,  
• outcome measures 
• number of participants in each group  





Quality assessment methods 
 
The methodological quality of the studies included will be assessed by means of a 
quality criteria checklist devised by two or more reviewers. 
 
 




• Summary of overall review findings 
• Quality ratings for each of the dimensions identified 
• Limitations of available research 
• Areas identified for future research 





• Chapter in portfolio doctoral thesis 
• Submitted for publication  
!
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Operationalisation of Quality Criteria 
 
 
1–A true clinical sample of patients is represented in the study 
 
Well covered Patients have been recruited in a clinical setting and a consecutive 
series of potential participants were approached, of which over 
70% completed the study 
Adequately 
addressed 
Patients have been recruited in a clinical setting but potential bias 
in those approached (e.g. the sample was not made up of a 
consecutive series or completion rates from consecutive sample 
were below 60%) 
Poorly addressed Not recruited in a clinical setting or a highly selected clinical 
sample 
Not addressed  
Not reported  
Not applicable  
Notes  
 
2– A suitably controlled design used 
 
Well covered A suitable control group (i.e. ‘treatment as usual’) was recruited 
alongside the intervention group.  
Adequately 
addressed 
An alternative intervention group (e.g. simpler educational 
pamphlet) was recruited but no control group (i.e. ‘treatment as 
usual’) 
Poorly addressed  
Not addressed No control group was recruited 
Not reported  
Not applicable  
Notes  
 Quality Criteria 
1 A true clinical sample of patients is represented in the study 
2 A suitably controlled design was used 
3 Assignment to groups is randomised 
4 Sample size was sufficient for analyses relating to knowledge and/or decisional conflict outcomes  
5 Similar levels of knowledge and/or decisional conflict between intervention and control groups, or differences were controlled for in analyses  
6 Knowledge outcome is measured in a valid and reliable way 
7 Decisional conflict outcome is measured in a valid and reliable way 
8 Appropriate analyses used 
9 Levels of attrition are reported and equivalent for treatment versus control 





3 –Assignment of subjects to the groups is randomised 
 
Well covered Clear information is given regarding the method of randomisation 
Adequately 
addressed 
Randomisation occurred although insufficient information given 
regarding methods used 
Poorly 
addressed 
Assignment to groups is not adequately described and may be non-
randomised 
Not addressed  
Not reported  




4 – Sample size was sufficient for analyses relating to knowledge and/or decisional conflict 
outcomes 
 
Well covered Number of participants who completed both pre and post intervention 
measure(s) was sufficient to enable Power of at least 0.8 for simple 
main effects (uncontrolled trials) and interaction effects (where 2 
groups). Effect size was anticipated to be medium and alpha was 0.05 
Adequately 
addressed 
Number of participants who completed both pre and post measure(s) 
was sufficient to enable Power of at least 0.7 for simple main effects 
(uncontrolled trials) and interaction effects (where 2 groups). Effect 
size was anticipated to be medium and alpha was 0.05 
Poorly 
addressed 
Number of participants who completed both pre and post measure(s) 
was only sufficient to enable Power less than 0.7 for simple main 
effects (uncontrolled trials) and interaction effects (where 2 groups). 
Effect size was anticipated to be medium and alpha was 0.05 
Not addressed  
Not reported  





5–Similar levels of knowledge and/or decisional conflict between intervention and control groups, 




Baseline measures of knowledge and/or decisional conflict were 
sufficiently alike between conditions (difference within 0.5 standard 
deviations on measures), or any differences were suitably controlled 
for in analyses (e.g. via ANCOVA). 
Adequately 
addressed 
Baseline measures of knowledge and/or decisional conflict were 
somewhat alike between conditions (difference within 1.0 standard 
deviations on measures), but not suitably controlled for in analyses 
(e.g. via ANCOVA). 
Poorly 
addressed 
Baseline measures of knowledge and/or decisional conflict were not 
alike between conditions (difference more than 1.0 standard 








6– Knowledge outcome was measured in a valid and reliable way 
 
 
Well covered Standardised outcome measure(s) used with well-reported 
psychometric properties (i.e. valid and reliable) in the cancer 
population that the decision aid was designed for 
Adequately 
addressed 




Non-standardised outcome measures used. 
Not addressed  
Not reported  




7 – Decisional conflict outcome was measured in a valid and reliable way 
 
Well covered Standardised outcome measure(s) used with well-reported 
psychometric properties (i.e. valid and reliable) in the cancer 
population that the decision aid was designed for (e.g. the 
Decisional Conflict Scale). 
Adequately 
addressed 




Non-standardised outcome measures used. 
Not addressed  
Not reported  
Not applicable  
Notes  
 
   
8 –Appropriate analysis 
 
Well covered Analysis described sufficiently to determine that analyses conducted 
appropriately post-intervention-appropriate statistics used. 
Adequately 
addressed 
Reasonably clear that appropriate analysis carried out post-




Inappropriate analyses post-intervention 
Not addressed  
Not reported  






9- Levels of attrition were equivalent for treatment versus control 
 
Well covered Levels of attrition (from allocation to completion of post-
intervention measures) for both treatment and control group 
(where present) are sufficiently alike (within 10% of each other) 
Adequately 
addressed 
Levels of attrition (from allocation to completion of post-
intervention measures) for both treatment and control group 
(where present), are somewhat alike (within 20% of each other) 
Poorly addressed Levels of attrition are significantly different between conditions 
Not addressed Levels of attrition not described 
Not reported  




10 – The intervention is evaluated for an appropriate duration 
 
Well covered Follow-up carried out for a minimum of 3 months (where 
measures of knowledge and/or decisional conflict were completed 
as at post-intervention) 
Adequately 
addressed 
Follow-up carried out for a minimum of 1 month (where measures 
of knowledge and/or decisional conflict were completed as at post-
intervention) 
Poorly addressed Follow-up less than one month carried out 
Not addressed No longer term follow-up carried out 
Not reported  







Appendix 4. NHS Lothian Ethics Approval Letter 
 
   
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
 Please note: the author’s maiden name at the time of data collection was Kelly and is now Wilson. 
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Appendix 5. Site Specific Approval Email 
!
From: Gorman, Clare 
Sent: 20 August 2012 15:51 
To: Kelly, Fiona E 
 





Many thanks for your email. 





Cancer and Palliative Care Services 




Appendix 6. Patient Study Information Sheet 
 
                                                !
!
Patient Participant Information Sheet 
 
Study: The CA-125 Decision Aid Development Study for Ovarian Cancer. 
 
 
You are being invited to take part in a research study.  Before you decide whether or not to 
take part, it is important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully. Talk to others about the 
study if you wish.  Contact us if there is anything that is not clear or if you would like more 
information.  Take time to decide whether or not you wish to take part. 
 
What is the purpose of the study? 
The aim of the study is to identify women’s decisional support needs related to the CA-125 
blood test used for the post-treatment monitoring of epithelial ovarian cancer. The results of 
this study will then be used to develop a decision aid tool for women who have completed 
their primary treatment (i.e. surgery and chemotherapy) for epithelial ovarian cancer and are 
considering whether or not to have regular CA-125 tests. The decision aid will be a booklet 
which helps women to make this decision by providing evidence-based information about the 
options and possible outcomes, as well as leading the individual through a process of 
understanding their values and preferences before decision-making. 
 
Why have I been asked to take part? 
You have been asked to take part as you have previously been diagnosed with epithelial 
ovarian cancer, have already completed your primary treatment and have made the decision to 
have or not to have CA-125 monitoring at least six months ago. We are inviting women who 
have already gone through this decision-making process in order to gain an understanding of 
what it is like to make this decision so that we can use this information to help women who 





Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you do decide to take part you will 
be given this information sheet to keep and be asked to sign a consent form. If you decide to 
take part you are still free to withdraw at any time and without giving a reason. Deciding not 
to take part or withdrawing from the study will not affect the healthcare you receive in any 
way. 
 
What will happen if I take part? 
If you decide to take part, please keep this information sheet and sign the attached consent 
form and return it to the researcher. The researcher will then contact you by telephone to 
arrange to meet with you at a time and place that is convenient for you to conduct the 
interview.  
During the interview, the researcher will ask you some questions about your knowledge of the 
CA-125 test, your decision to have or not to have regular CA-125 tests and your thoughts and 
feelings now about the decision you made. The interview will take no longer than one hour, 
and will be recorded with a small audio recording device so that the researcher can listen back 
to it and examine the information you give in conjunction with interviews from other 
participants. At the end of this interview, you will be invited to participate in the evaluation 
stage of the project where you will be asked for your opinion on the decision aid produced. It 
is completely your choice whether or not you wish to take part in this later phase of the 
project and you are under no obligation to do so.  
 
Will my taking part in this study be kept confidential? 
Yes. Your participation in this study will be kept anonymous and those who read the final 
report will not have any way of identifying that you took part. Only the lead researcher will 
have access to the recording of your interview. This will be transferred onto a secure 
password protected NHS Lothian computer as soon as possible and deleted from the 
recording device. All the information we collect during the course of the research will be kept 
confidential and there are strict laws that safeguard your privacy at every stage. Your name 
will be removed from the data so that you cannot be recognised from it.  Typed interview 
transcripts will also be fully anonymised, and will be stored securely on NHS premises. 
Transcripts and recordings will be archived as per NHS Lothian Research & Development 
Department (Crown Records Management) protocol, and NHS Lothian R&D has a nominated 
individual who has overall responsibility for archiving within the department. Direct quotes 
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from your interview may be published in the final report, however, these will be fully 
anonymized and you will not be identifiable. With your consent, we will inform your GP that 
you are taking part.  
Under those exceptional circumstances under which there appears sufficient evidence to raise 
serious concern about your safety or the safety of others, confidentiality may not be 
maintained. If this happens, the researcher will need to discuss her concerns regarding your 
safety or the safety of others with colleagues and follow up any concerns they may have with 
management and other relevant people. If this happens, your data will no longer be required 
for the study. This will be discussed with you in more detail before the interview, and you 
will have the opportunity to ask the researcher any questions at this time. 
 
What are the possible benefits of taking part? 
By taking part in this study, you will have the opportunity to directly contribute to the 
development of a decision aid tool that will help other women with ovarian cancer who are 
facing the difficult decision of having CA-125 monitoring or not. 
 
What are the possible disadvantages and risks of taking part? 
Whilst the focus of the interview is on your decision to have CA-125 monitoring or not, we 
understand that you may feel upset by talking about something closely related to your cancer 
diagnosis and your experience of living with cancer. You will be reminded at the start of the 
interview that if you feel any distress or get upset to either ask for a break or request to stop 
the interview altogether. You may also choose to not answer any questions you feel 
uncomfortable answering. Additional support from staff at the Edinburgh Cancer Centre will 
also be available if you need it, including a referral to the clinical psychology service if 
necessary. If you are concerned about experiencing distress during or following the interview, 
then we advise that you do not participate.  
 
What will happen to the results of the study? 
The study will be written up as a Clinical Psychology Doctoral Thesis, and will be available 
electronically and manually through the University of Edinburgh library. The final results 
may also be shared through conferences and peer reviewed scientific journals. Your 
identification will not be included in any publication. We will also send each participant a 






Who is organising the research and why? 
This study is being organised and funded by the University of Edinburgh in collaboration 
with NHS Lothian. 
 
Who has reviewed the study? 
The study proposal has been reviewed by the lead researcher’s academic supervisor at 
University of Edinburgh and clinical supervisor at the Edinburgh Cancer Centre. The study 
has also been reviewed by two Consultant Oncologists at the Edinburgh Cancer Centre. A 
favourable ethical opinion has also been obtained from South East Scotland REC 01.  NHS 
management approval has also been obtained. 
 
If you have any further questions about the study please contact Fiona Kelly by phone 
0131 537 3094 or email fiona.e.kelly@nhslothian.scot.nhs.uk. 
 
If you would like to discuss this research with someone independent of the study please 
contact: Claire Gittoes, Trainee Clinical Psychologist, Pennywell Resource Centre (Tel: 
0131 537 4217). Claire works as a Trainee Clinical Psychologist for NHS Lothian, and is also 
enrolled on the University of Edinburgh Clinical Psychology Doctoral Programme. 
 
If you wish to make a complaint about the study please contact NHS Lothian: 
NHS Lothian Complaints Team 
2nd Floor 
Waverley Gate 
2-4 Waterloo Place 
Edinburgh 
EH1 3EG 
Tel: 0131 465 5708 
 
 









Patient Participant Consent Form  
 
Project Title: The CA-125 Decision Aid Development Study for Ovarian Cancer. 
Name of Chief Investigator:  Dr Fiona Kelly 
                                                  Ph: 0131 537 3094 
                                      
Thank you for reading the information about our research project. If you would like to take 
part, please read and sign this form. 
 






1. I confirm that I have read and understand the participant information sheet dated 




2. I understand that participation is voluntary and that I am free to withdraw at any 




3. I agree that the audio information I provide in the interview can be audiotaped 
and transcribed. I understand that the audio recording will be deleted at the end 
of the project. 
 
4. I understand that research data obtained during the study will be fully 
anonymised so that others could not identify me. This unidentifiable research 
data may then be stored and used for purposes in the public interest. 
 
 
5.        I understand that under those exceptional circumstances under which there 
appears sufficient evidence to raise serious concern about my safety or the 
safety of others, confidentiality may not be maintained. 
 
 




7.       I agree to take part in the above study and that if the study is published, I 
understand that all data will be fully anonymised and I will not be identifiable. 
 
8.        I allow NHS Lothian, as a sponsor of this study to access my medical records to 


















Thank you for agreeing to participate in this research.  
!
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Appendix 8. Health Professional Study Information Sheet 
 
                                                !
 
Health Professional Participant Information Sheet 
 
Study: The CA-125 Decision Aid Development Study for Ovarian Cancer. 
 
You are being invited to take part in a research study.  Before you decide whether or not to 
take part, it is important for you to understand why the research is being done and what it will 
involve.  Please take time to read the following information carefully. Talk to others about the 
study if you wish.  Contact us if there is anything that is not clear or if you would like more 
information.  Take time to decide whether or not you wish to take part. 
 
What is the purpose of the study? 
The aim of the study is to identify women’s decisional support needs related to the CA-125 
test used for the post-treatment monitoring of epithelial ovarian cancer. The results of this 
study will then be used to develop a decision aid tool for women who have completed their 
primary treatment (i.e. surgery and chemotherapy) for epithelial ovarian cancer and are 
considering whether or not to have regular CA-125 tests. The decision aid will be a booklet 
which helps women to make this decision by providing evidence-based information about the 
options and possible outcomes, as well as leading the individual through a process of 
understanding their values and preferences before decision-making. 
 
Why have I been asked to take part? 
You have been asked to take part because you are currently a staff member involved in the 
direct medical care of women with epithelial ovarian cancer at the Edinburgh Cancer Centre. 
 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. If you do decide to take part you will 
be given this information sheet to keep and be asked to sign a consent form. If you decide to 





What will happen if I take part? 
If you decide to take part, please keep this information sheet and sign the attached consent 
form and return it to the researcher. The researcher will then contact you by telephone to 
arrange to meet with you at the Edinburgh Cancer Centre at a date and time that is convenient 
for you to conduct the interview.  
During the interview, the researcher will ask you some questions about your current practice 
regarding use of the test, your opinion on the recent results from the MRC OVO5 trial and 
your opinion on the advantages and disadvantages of CA125 testing for women entering post-
treatment surveillance. The interview will last about an hour, and will be recorded with a 
small audio recording device so that the researcher can listen back to it and examine the 
information you give in conjunction with interviews from other participants. At the end of 
this interview, you will be invited to participate in the evaluation stage of the project where 
you will be asked for your opinion on the decision aid produced. It is completely your choice 
whether or not you wish to take part in this later phase of the project and you are under no 
obligation to do so.  
 
Will my taking part in this study be kept confidential? 
Yes. Your participation in this study will be kept anonymous and those who read the final 
report will not have any way of identifying that you took part. Only the lead researcher will 
have access to the recording of your interview. This will be transferred onto a secure 
password protected NHS Lothian computer as soon as possible and deleted from the 
recording device. All the information we collect during the course of the research will be kept 
confidential and there are strict laws that safeguard your privacy at every stage. Your name 
will be removed from the data so that you cannot be recognised from it.  Typed interview 
transcripts will also be fully anonymised, and will be stored securely on NHS premises. 
Transcripts and recordings will be archived as per NHS Lothian Research & Development 
Department (Crown Records Management) protocol, and NHS Lothian R&D has a nominated 
individual who has overall responsibility for archiving within the department. Direct quotes 
from your interview may be published in the final report, however, these will be fully 
anonymized and you will not be identifiable.  
 
What are the possible benefits of taking part? 
By taking part in this study, you will have the opportunity to directly contribute your 
knowledge and skills to inform the development of a decision aid tool which is anticipated to 
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greatly improve the decision-making process for women at this stage of decision-making and 
which will also be of considerable value during patient-doctor consultations. 
 
What are the possible disadvantages and risks of taking part? 
As this interview is focused on your knowledge of the CA-125 test and your opinion on its 
use in current practice we do not anticipate any possible disadvantages or risks if you take 
part. 
 
What will happen to the results of the study? 
The study will be written up as a Clinical Psychology Doctoral Thesis, and will be available 
electronically and manually through the University of Edinburgh library. The final results 
may also be shared through conferences and peer reviewed scientific journals. Your 
identification will not be included in any publication. We will also send each participant a 
copy of the final decision aid booklet in gratitude of their participation. 
 
Who is organising the research and why? 
This study is being organised and funded by the University of Edinburgh in collaboration 
with NHS Lothian. 
 
Who has reviewed the study? 
The study proposal has been reviewed by the lead researcher’s academic supervisor at 
University of Edinburgh and clinical supervisor at the Edinburgh Cancer Centre. The study 
has also been reviewed by two Consultant Oncologists at the Edinburgh Cancer Centre. A 
favourable ethical opinion has also been obtained from South East Scotland REC 01.  NHS 
management approval has also been obtained. 
 
 
If you have any further questions about the study please contact Fiona Kelly by phone 
0131 537 3094 or email fiona.e.kelly@nhslothian.scot.nhs.uk. 
 
 











Health Professional Participant Consent Form  
 
Project Title:  The CA-125 Decision Aid Development Study for Ovarian Cancer. 
Name of Chief Investigator: Dr Fiona Kelly 
                                                Ph: 0131 537 3094 
                                      
Thank you for reading the information about our research project. If you would like to take 
part, please read and sign this form. 
 







1. I confirm that I have read and understand the participant information sheet 




1. I understand that participation is voluntary and that I am free to withdraw at 




2. I agree that the audio information I provide in the interview can be audiotaped, 
transcribed, stored with my name removed from all records and my words used 
in the presentation of the research. I understand that my words will not be used 
to identify me. 
 
3. I understand that the any data obtained during the study will be fully 




5.       I agree to take part in the above study and that if the study is published, I 
understand that all data will be fully anonymized and I will not be identifiable. 
 
______________________ 


















Appendix 10. Patient Interview Schedule 
 
 
Semi-Structured Interview for Patient Participants  
 
Part one:  
 
Knowledge surrounding the CA-125 test and its purpose post-treatment 
 
1. Introduce patient vignette 
2. Can you tell me what you know about the CA-125 test? Prompt if necessary: What 
does it measure? 
3.What is your understanding about the function of CA-125 testing during post-
treatment surveillance/follow-up care for ovarian cancer? 
 
 
Questions about the decision-making process 
 
4. What information did you receive about the CA-125 test post-treatment?  
5. Did your oncologist outline the pros and cons of having regular CA-125 testing? 
6. What was helpful about the information you received in aiding your decision- 
making? 
7. What was unhelpful? 
8. Did you feel that you were given adequate time to make this decision? 
9. Were you advised to go away and think about it or consult family/friends about it? 
10. Did you make the decision on the spot or did you take some time? 
11. Did you discuss the decision with family/friends? 
12. Did you look for any additional information about CA-125 testing to help with 
your decision-making? Prompt if necessary: For example, on the internet? 
13. Overall, what factors influenced your final decision? 
 
 
Anxiety-related questions for women who chose to have CA-125 monitoring 
 
14. Has the decision to have regular CA-125 testing prior to your clinic visits caused 
you to experience any anxiety?  
15. Do you worry about your CA-125 count/level in general? 
16. Do you feel that having the CA-125 test has impacted upon your quality of life in 
any way?  
 
Part two: Opinion on the use and development of a decision aid tool regarding this 
decision 
 
Participant is shown an example of a decision aid tool produced by Anderson et al 
(2011) to explain the function of such a tool in aiding decision-making. 
 
17. Do you think that such a tool would be useful for patients making the decision 
regarding post-treatment CA 125 surveillance? If so, why? 
!
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18. When you made your decision about CA-125 testing, would other women’s 
stories about how they made their decision have been helpful to know? 
Why/why not? 
19. Do you think that it would be helpful to include patient stories in a decision 
aid about CA-125 testing during post-treatment surveillance? Why/why not? 
20.  Where do you think would be the best place for patients to use the decision 
aid? Why? 
21. When do you think would be the best time for patients to be given the decision 
aid for helping with their decision-making? Why? 
 
 
Part three: Possible decision options 
 
Participants are shown the three CA-125 post-therapy options proposed by Rustin 
(2011) and asked for their opinion on the inclusion of all three options in the decision 
aid or the possibility of only including options 1 and 2 (i.e. to have the test or to not 







Appendix 11. Health Professional Interview Schedule 
 
Semi-Structured Interview for Health Professionals 
 
 
Part one:  
 
Questions regarding current practice & advantages/disadvantages of CA-125 testing 
 
1. What is your current practice regarding CA-125 testing? 
2. How would you typically discuss the test with women post-treatment? 
3. What in your opinion, are the advantages and disadvantages of CA-125 testing for 
women? 
4. What are the advantages and disadvantages for you as the health professional in 
charge of their care? 
5. If you were a patient and had to make a decision to have CA-125 post-treatment 
surveillance or not, what would you choose and why? 
 
Questions about the OVO5 European Trial 
 
6. What is your opinion on the results of the recent MRC OVO5 trial? 
7. Have the results influenced your practice regarding the CA-125 test? 
8. Did the results surprise you?  
 
 
Part two: Opinion on the use and development of a decision aid tool regarding this 
decision 
 
The health professional is shown an example of a decision aid tool produced by 
Anderson et al (2011) to explain the function of such a tool in aiding decision-
making. 
 
9. Do you think that such a tool would be useful for patients making the decision 
regarding post-treatment CA-125 surveillance? If so, why? 
10. Would you find such a tool helpful during your consultation? 
11. Where do you think would be the best place for patients to use the decision aid? 
Why? 
12. When do you think would be the best time for patients to be given the decision aid 
for helping with their decision-making? Why? 
 
 
Part three: Possible decision options 
 
Participants are shown the three CA-125 post-therapy options proposed by Rustin 
(2011) and asked for their opinion on the inclusion of all three options in the decision 
aid or the possibility of only including options 1 and 2 (i.e. to have the test or to not 
have the test).  
 
